JCI - Citations to New and emerging HDAC inhibitors for cancer treatment

Citations to this article

New and emerging HDAC inhibitors for cancer treatment

Alison C. West, Ricky W. Johnstone

Alison C. West, Ricky W. Johnstone

Published January 2, 2014
Citation Information: J Clin Invest. 2014;124(1):30-39. https://doi.org/10.1172/JCI69738.

View: Text | PDF

Total citations by year

Year:	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2009	Total
Citations:	19	32	47	59	68	56	75	72	95	82	61	22	1	689

Citation information

Citations to this article (689)

Title and authors	Publication	Year
Lactylation of HDAC1 confers resistant to ferroptosis in colorectal cancer Zhou Yang, Wei Su, Qinglin Zhang, Lili Niu, Baijie Feng, Yu Zhang, Jiaxin He, Qinyao Zhou, Xin Zhou, Longjun Ma, Jingwan Zhou, Yuanrong Wang, Wenjing Xiong, Jun Xiang, Zhilin Hu, Qiang Zhan, Bing Yao	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2025
Targeting protein modification: a new direction for immunotherapy of pancreatic cancer Ge X, Zhang K, Zhu J, Chen Y, Wang Z, Wang P, Xu P, Yao J	International Journal of Biological Sciences	2025
Metal Ion Signaling in Biomedicine Rodriguez R, Müller S, Colombeau L, Solier S, Sindikubwabo F, Cañeque T	Chemical Reviews	2025
Human immune system: Exploring diversity across individuals and populations Hoang Nguyen KH, Le NV, Nguyen PH, Nguyen HH, Hoang DM, Huynh CD	Heliyon	2025
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response Yao M, Yan W, Wang Y, Zhao Y, Xu X, Chen Y, Yu C, Li Y, Jiang H, Shen J, Cheng J, Xie C	Experimental Hematology & Oncology	2025
The epigenetic hallmarks of immune cells in cancer Ji Y, Xiao C, Fan T, Deng Z, Wang D, Cai W, Li J, Liao T, Li C, He J	Molecular Cancer	2025
The role of fructose-1,6-bisphosphatase 1 on regulating the cancer progression and drug resistance Wang M, Huang X, Zhang D, Liu Y, Liu P	Discover Oncology	2025
Genetically encoding ε-N-methacryllysine into proteins in live cells Zhu TY, Chen SY, Zhang M, Li H, Wu T, Ajiboye E, Wang JW, Jin BK, Liu DD, Zhou X, Huang H, Wan X, Sun K, Lu P, Fu Y, Yuan Y, Song H, Sablina AA, Tong C, Zhang L, Wu M, Wu H, Yang B	Nature Communications	2025
Unveiling the Role of Protein Posttranslational Modifications in Glioma Prognosis Jiang Z, Huang H, Guo Y, Wang Z, Huang H, Yin W, Huang H, Wang L, Liu W, Jiang X, Ren C	CNS Neuroscience & Therapeutics	2025
Computationally Guided Design, Synthesis, and Evaluation of Novel Non-Hydroxamic Histone Deacetylase Inhibitors, Based on N-Trifluoroacetamide as a Zinc-Binding Group, Against Breast Cancer Morales-Herrejón G, García-Vázquez JB, Fernández-Pomares C, Bakalara N, Correa-Basurto J, Mendoza-Figueroa HL	Pharmaceuticals	2025
Unlocking the Therapeutic Potential of Patchouli Leaves: A Comprehensive Review of Phytochemical and Pharmacological Insights Mrisho II, Musazade E, Chen H, Zhao H, Xing J, Li X, Han J, Cai E	Plants	2025
Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancer Fathy A, Allam A, ElHady AK, El-Gamil DS, Lin KC, Chang YH, Lee YH, Hilscher S, Schutkowski M, Ibrahim HS, Chen SH, Chen CH, Abadi AH, Sippl W, Chen PJ, Cheng YS, Abdel-Halim M	RSC Medicinal Chemistry	2025
Combination of Sodium Butyrate and Immunotherapy in Glioma: regulation of immunologically hot and cold tumors via gut microbiota and metabolites Li S, Wang L, Han M, Fan H, Tang H, Gao H, Li G, Xu Z, Zhou Z, Du J, Peng C, Peng F	Frontiers in Immunology	2025
Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Cirstea D, Shome R, Samur M, Talluri S, Connolly JJ, Wright AJ, Duvallet E, Joyce AN, Lively K, Basinsky G, Yee AJ, Chase CC, Malek E, Niesvizky R, Richardson PG, Raje NS	Blood Cancer Journal	2025
Mechanisms of HDACs in cancer development Zhang Y, Wang H, Zhan Z, Gan L, Bai O	Frontiers in Immunology	2025
Identification and targeting of regulators of SARS-CoV-2–host interactions in the airway epithelium Dirvin B, Noh H, Tomassoni L, Cao D, Zhou Y, Ke X, Qian J, Jangra S, Schotsaert M, García-Sastre A, Karan C, Califano A, Cardoso WV	Science Advances	2025
Simulated Microgravity-Induced Alterations in PDAC Cells: A Potential Role for Trichostatin A in Restoring Cellular Phenotype Pagano CA, Masini MA, Sabbatini M, Gribaudo G, Manfredi M, Caprì FG, Bonetto V, Magnelli V, Donadelli M, Corino R, Belay MH, Robotti E, Marengo E	International Journal of Molecular Sciences	2025
Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications Wang Z, Zhu X, Huang Z, Ren K, Ran J, Yang Y	Advanced Science	2025
The hydroxamate based HDAC inhibitor WMJ-J-09 induces colorectal cancer cell death by targeting tubulin and downregulating survivin Huang YH, Huang YM, Huang WJ, Yu MC, Chuang CH, Hsu YF, Chen HC, Chen LC, Huang SW, Hsu MJ	Scientific Reports	2025
New progress in the treatment of diffuse midline glioma with H3K27M alteration Yang Z, Sun L, Chen H, Sun C, Xia L	Heliyon	2024
HDAC inhibitors directly modulate T cell gene expression and signaling and promote development of effector-exhausted T cells in murine tumors Ibrahim ML, Zheng H, Barlow ML, Latif Y, Chen Z, Yu X, Beg AA	Journal of immunology (Baltimore, Md. : 1950)	2024
Epigenetic Mechanisms Histone Deacetylase–Dependent Regulate the Glioblastoma Angiogenic Matrisome and Disrupt Endothelial Cell Behavior In Vitro Menezes A, Julião G, Mariath F, Ferreira AL, Oliveira-Nunes MC, Gallucci L, Evaristo JA, Nogueira FC, Pereira DD, Carneiro K	Molecular & cellular proteomics : MCP	2024
The therapeutic potential of targeting the CHD protein family in cancer Zhang M, Wu K, Zhang W, Lin X, Cao Q, Zhang L, Chen K	Pharmacology & Therapeutics	2024
Attenuation of neuronal ferroptosis in intracerebral hemorrhage by inhibiting HDAC1/2: Microglial heterogenization via the Nrf2/HO1 pathway Jiang Z, Yang H, Ni W, Gao X, Pei X, Jiang H, Su J, Weng R, Fei Y, Gao Y, Gu Y	CNS Neuroscience & Therapeutics	2024
The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis Barcutean L, Maier S, Burai-Patrascu M, Farczadi L, Balasa R	International journal of molecular sciences	2024
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms. Nagy A, Börzsei D, Hoffmann A, Török S, Veszelka M, Almási N, Varga C, Szabó R	Cardiovascular Drugs and Therapy	2024
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives Pu J, Liu T, Wang X, Sharma A, Schmidt-Wolf IG, Jiang L, Hou J	Experimental Hematology and Oncology	2024
Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs. Zhang W, Jiao B, Yu S, Zhang C, Zhang K, Liu B, Zhang X	CNS Neuroscience & Therapeutics	2024
Histone deacetylase 3-specific inhibitor RGFP966 attenuates oxidative stress and inflammation after traumatic brain injury by activating the Nrf2 pathway. Xu L, An T, Jia B, Wu Q, Shen J, Jin J, Liu J, Li C	Burns & Trauma	2024
Advances in targeting histone deacetylase for treatment of solid tumors Shi MQ, Xu Y, Fu X, Pan DS, Lu XP, Xiao Y, Jiang YZ	Journal of Hematology & Oncology	2024
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods Curcio A, Rocca R, Alcaro S, Artese A	Pharmaceuticals	2024
Incorporation of Multiple β2-Hydroxy Acids into a Protein In Vivo Using an Orthogonal Aminoacyl-tRNA Synthetase Hamlish NX, Abramyan AM, Shah B, Zhang Z, Schepartz A	ACS Central Science	2024
Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues Kumar KK, Aburawi EH, Ljubisavljevic M, Leow MK, Feng X, Ansari SA, Emerald BS	Clinical Epigenetics	2024
Phase II Study of the Novel Antifolate Agent Pralatrexate in Combination with the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients with MatureT-Cell Lymphoma Tiger YK, Jain S, Barta SK, Tolu S, Estrella B, Sawas A, Lue JK, Francescone MM, Pro B, Amengual JE	Leukemia & Lymphoma	2024
Diffuse Intrinsic Pontine Glioma (DIPG): A Review of Current and Emerging Treatment Strategies Weisbrod LJ, Thiraviyam A, Vengoji R, Shonka N, Jain M, Ho W, Batra SK, Salehi A	Cancer Letters	2024
Histone Deacetylases in Retinoblastoma Lisek M, Tomczak J, Swiatek J, Kaluza A, Boczek T	International journal of molecular sciences	2024
Acquired Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Resistance of Human Colorectal Cancer Cells Is Linked to Histone Acetylation and Is Synergistically Ameliorated by Combination with HDAC Inhibitors. Kim SL, Shin M, Jin BC, Seo S, Ha GW, Kim SW	Digestive Diseases and Sciences	2024
Acetylation of Steroidogenic Acute Regulatory Protein Sensitizes 17β-Estradiol Regulation in Hormone-Sensitive Breast Cancer Cells Manna PR, Molehin D, Ahmed AU, Yang S, Reddy PH	International Journal of Molecular Sciences	2024
Targeted small molecule therapy and inhibitors for lymphoma Wang ZH, Zheng X, Rao GW, Zheng Q	Future Medicinal Chemistry	2024
Sodium Butyrate (NaB) and Sodium Propionate (NaP) Reduce Cyclin A2 Expression, Inducing Cell Cycle Arrest and Proliferation Inhibition of Different Breast Cancer Subtypes, Leading to Apoptosis Ibrahim JN, El-Hakim S, Semaan J, Ghosn S, El Ayoubi H, Elnar AA, Tohme N, El Boustany C	Biomedicines	2024
Identification of HDAC10 as a candidate oncogene in clear cell renal carcinoma that facilitates tumor proliferation and metastasis Yang L, Wei Q, Chen X, Yang Y, Huang Q, Wang B, Ma X	Diagnostic Pathology	2024
ER-associated degradation ligase HRD1 links ER stress to DNA damage repair by modulating the activity of DNA-PKcs Xiang Z, Hou G, Zheng S, Lu M, Li T, Lin Q, Liu H, Wang X, Guan T, Wei Y, Zhang W, Zhang Y, Liu C, Li L, Lei QY, Hu Y	Proceedings of the National Academy of Sciences of the United States of America	2024
Synthesis and biological evaluation of ortho-phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases Hsu KC, Huang YY, Chu JC, Huang YW, Hu JL, Lin TE, Yen SC, Weng JR, Huang WJ	Journal of Enzyme Inhibition and Medicinal Chemistry	2024
The identification of potent dual-target monopolar spindle 1 (MPS1) and histone deacetylase 8 (HDAC8) inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulations, and biological evaluation Hua H, Guan L, Pan B, Gao J, Geng Y, Niu MM, Li Z, Li J	Frontiers in Pharmacology	2024
Therapeutic targeting of senescent cells in the CNS. Riessland M, Ximerakis M, Jarjour AA, Zhang B, Orr ME	Nature reviews. Drug discovery	2024
The Advances in the Development of Epigenetic Modifications Therapeutic Drugs Delivery Systems Li T, Chen Y, Li S	International Journal of Nanomedicine	2024
Identification and Targeting of Regulators of SARS-CoV-2-Host interactions in the Airway Epithelium Dirvin B, Noh H, Tomassoni L, Cao D, Zhou Y, Ke X, Qian J, Schotsaert M, García-Sastre A, Karan C, Califano A, Cardoso WV	bioRxiv	2024
Butyrate: a bridge between intestinal flora and rheumatoid arthritis Cao Y, Chen J, Xiao J, Hong Y, Xu K, Zhu Y	Frontiers in Immunology	2024
Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics Simulations Curcio A, Rocca R, Chiera F, Gallo Cantafio ME, Valentino I, Ganino L, Murfone P, De Simone A, Di Napoli G, Alcaro S, Amodio N, Artese A	Antioxidants	2024
Epigenetics-targeted drugs: current paradigms and future challenges Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S, Li T, Jiang Y, Wei S, Na Z, Xiao X, Li D	Signal Transduction and Targeted Therapy	2024
Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma Tu Y, Wu H, Zhong C, Liu Y, Xiong Z, Chen S, Wang J, Wong PP, Yang W, Liang Z, Lu J, Chen S, Zhang L, Feng Y, Si-Tou WW, Yin B, Lin Y, Liang J, Liang L, Vong JS, Ren W, Kwong TT, Leung H, To KF, Ma S, Tong M, Sun H, Xia Q, Zhou J, Kerr D, La Thangue N, Sung JJ, Chan SL, Cheng AS	Gut	2024
Assessment of HDAC Inhibitor-Induced Endoplasmic Reticulum (ER) Stress. Halilovic M, Marx-Blümel L, Marx C, Buder K, Beck JF, Sonnemann J	Methods in molecular biology (Clifton, N.J.)	2023
Expression and Function of StAR in Cancerous and Non-Cancerous Human and Mouse Breast Tissues: New Insights into Diagnosis and Treatment of Hormone-Sensitive Breast Cancer Manna PR, Ramachandran S, Pradeepkiran JA, Molehin D, Castro-Piedras I, Pruitt K, Ganapathy V, Reddy PH	International journal of molecular sciences	2023
Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy Parab A, Kumar Bhatt L, Omri A	Biomedicines	2023
Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways Lim JS, Kyung SY, Jeon Y, Kim IS, Kwak JH, Kim HS	Oncology reports	2023
Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study Li XY, Han XW, Huang K, Zhang YT, Xu HG, Zhou DH, Xu LH, Fang JP	Frontiers in Medicine	2023
Heterocycles in Breast Cancer Treatment: The Use of Pyrazole Derivatives. Ardevines S, Marqués-López E, Herrera RP	Current medicinal chemistry	2023
Circular RNA circ_0000741/miR-379-5p/TRIM14 signaling axis promotes HDAC inhibitor (SAHA) tolerance in glioblastoma. Meng L, Wang Y, Tu Q, Zhu Y, Dai X, Yang J	Metabolic Brain Disease	2023
Regulation of SUMOylation on RNA metabolism in cancers Cao Y, Huang C, Zhao X, Yu J	Frontiers in Molecular Biosciences	2023
Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer. Rezaeian AH, Phan LM, Zhou X, Wei W, Inuzuka H	Neoplasia (New York, N.Y.)	2023
HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non–small cell lung cancer Eichner LJ, Curtis SD, Brun SN, McGuire CK, Gushterova I, Baumgart JT, Trefts E, Ross DS, Rymoff TJ, Shaw RJ	Science Advances	2023
Role of epigenetics in OSCC: an understanding above genetics. Vatsa PP, Jindal Y, Bhadwalkar J, Chamoli A, Upadhyay V, Mandoli A	Medical Oncology	2023
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Elbezanti WO, Challagundla KB, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK	Pharmaceuticals (Basel, Switzerland)	2023
The landscape of cryptic antisense transcription in human cancers reveals an oncogenic noncoding RNA in lung cancer Zhao Z, Chen Y, Cheng X, Huang L, Wen H, Xu Q, Zhou X, Zhang X, Chen J, Ni T	Science Advances	2023
Metabolic reprogramming by immune-responsive gene 1 up-regulation improves donor heart preservation and function Lei I, Huang W, Noly PE, Naik S, Ghali M, Liu L, Pagani FD, Ela AA, Pober JS, Pitt B, Platt JL, Cascalho M, Wang Z, Chen YE, Mortensen RM, Tang PC	Science Translational Medicine	2023
Macrocyclic Octapeptide Binding and Inferences on Protein Substrate Binding to Histone Deacetylase 6 Watson PR, Gupta S, Hosseinzadeh P, Brown BP, Baker D, Christianson DW	ACS chemical biology	2023
Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma Peng X, Yu Z, Surineni G, Deng B, Zhang M, Li C, Sun Z, Pan W, Liu Y, Liu S, Yu B, Chen J	Journal of Enzyme Inhibition and Medicinal Chemistry	2023
Histone Deacetylase 1 Inhibition by Peptides Containing a DNA Damage-Induced, Nonenzymatic, Histone Covalent Modification. Jacinto MP, Greenberg MM	Biochemistry	2023
The Role of Histone Deacetylases in Acute Lung Injury—Friend or Foe Luo G, Liu B, Fu T, Liu Y, Li B, Li N, Geng Q	International journal of molecular sciences	2023
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma Villarruel-Melquiades F, Mendoza-Garrido ME, García-Cuellar CM, Sánchez-Pérez Y, Pérez-Carreón JI, Camacho J	World Journal of Gastroenterology	2023
Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone. Ono T, Noguchi R, Yoshimatsu Y, Sin Y, Tsuchiya R, Akiyama T, Kojima N, Toda Y, Sato C, Fukushima S, Yoshida A, Kawai A, Kondo T	Human Cell	2023
Sirtuin Inhibitor Cambinol Induces Cell Differentiation and Differently Interferes with SIRT1 and 2 at the Substrate Binding Site Giordano D, Scafuri B, De Masi L, Capasso L, Maresca V, Altucci L, Nebbioso A, Facchiano A, Bontempo P	Biomedicines	2023
Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor Drzewiecka M, Gajos-Michniewicz A, Hoser G, Jaśniak D, Barszczewska-Pietraszek G, Sitarek P, Czarny P, Piekarski J, Radek M, Czyż M, Skorski T, Śliwiński T	Genes & development	2023
The Synergistic Antitumor Effect of Decitabine and Vorinostat Combination on HepG2 Human Hepatocellular Carcinoma Cell Line via Epigenetic Modulation of Autophagy-Apoptosis Molecular Crosstalk. Salama BM, Helmy MW, Fouad H, Shamaa MM, Houssen ME	Current issues in molecular biology	2023
HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells Lyu H, Hou D, Liu H, Ruan S, Tan C, Wu J, Hicks C, Liu B	npj Precision Oncology	2023
Inhibition of EZH2 alleviates SAHA-induced senescence-associated secretion phenotype in small cell lung cancer cells. Kong SH, Ma L, Yuan Q, Liu X, Han Y, Xiang W, Liu DX, Zhang Y, Lu J	Cell Death Discovery	2023
Epigenetic and molecular coordination between HDAC2 and SMAD3-SKI regulates essential brain tumour stem cell characteristics. Bahia RK, Hao X, Hassam R, Cseh O, Bozek DA, Luchman HA, Weiss S	Nature Communications	2023
Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells. Tsai FL, Huang HL, Lai MJ, Liou JP, Pan SL, Yang CR	International journal of molecular sciences	2023
CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells. Liu X, Tian F, Cui J, Gong L, Xiang L, Fan B, Liu S, Zhan J, Zhou Y, Jiang B, Wang M, Sun G, Gong Y, Zou Y	Oncogene	2023
Quatramer™ encapsulation of dual‐targeted PI3‐Kδ/HDAC6 inhibitor, HSB‐510, suppresses growth of breast cancer Tiwari S, Liu S, Anees M, Mehrotra N, Thakur A, Tawa GJ, Grewal G, Stone R, Kharbanda S, Singh H	Bioengineering & Translational Medicine	2023
Enhancing Transcriptional Reprogramming of Mesenchymal Glioblastoma with Grainyhead-like 2 and HDAC Inhibitors Leads to Apoptosis and Cell-Cycle Dysregulation Kotian S, Carnes RM, Stern JL	Genes & development	2023
Glioma Stem Cells Are Sensitized to BCL-2 Family Inhibition by Compromising Histone Deacetylases Merati A, Kotian S, Acton A, Placzek W, Smithberger E, Shelton AK, Miller CR, Stern JL	International journal of molecular sciences	2023
Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells Drzewiecka M, Jaśniak D, Barszczewska-Pietraszek G, Czarny P, Kobrzycka A, Wieczorek M, Radek M, Szemraj J, Skorski T, Śliwiński T	Journal of Personalized Medicine	2023
Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma Yu Z, Ding M, Cai Y, Lu T, Chen X, Zhou X, Wang X	BMC Cancer	2023
Immune-epigenetic crosstalk in haematological malignancies Wong H, Sugimura R	Frontiers in Cell and Developmental Biology	2023
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M	Molecular Cancer	2023
Untargeted LC-MS/MS Metabolomics Study of HO-AAVPA and VPA on Breast Cancer Cell Lines Estrada-Pérez AR, García-Vázquez JB, Mendoza-Figueroa HL, Rosales-Hernández MC, Fernández-Pomares C, Correa-Basurto J	International journal of molecular sciences	2023
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance Sadida HQ, Abdulla A, Marzooqi SA, Hashem S, Macha MA, Akil AS, Bhat AA	Translational oncology	2023
Epigenetic Dysregulation and Its Correlation with the Steroidogenic Machinery Impacting Breast Pathogenesis: Data Mining and Molecular Insights into Therapeutics Manna PR, Yang S, Reddy PH	International journal of molecular sciences	2023
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Murphy T, Mason JM, Leber B, Bray MR, Chan SM, Gupta V, Khalaf D, Maze D, McNamara CJ, Schimmer AD, Schuh AC, Sibai H, Trus M, Valiquette D, Martin K, Nguyen L, Li X, Mak TW, Minden MD, Yee KWL	Leukemia	2023
Exploring the Molecular Underpinnings of Cancer-Causing Oncohistone Mutants Using Yeast as a Model Zhang X, Fawwal DV, Spangle JM, Corbett AH, Jones CY	Journal of Fungi	2023
A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors Drakontaeidi A, Pontiki E	Pharmaceuticals	2023
Peptidomics Unveils Distinct Acetylation Patterns of Histone and Annexin A1 in Differentiated Thyroid Cancer Coelho M, Capela J, Mendes VM, Pacheco J, Fernandes MS, Amendoeira I, Jones JG, Raposo L, Manadas B	International journal of molecular sciences	2023
Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell–cell fusion Nakatake M, Kurosaki H, Nakamura T	Cancer Science	2023
P53 together with ferroptosis: a promising strategy leaving cancer cells without escape. Zhan J, Wang J, Liang Y, Zeng X, Li E, Wang H	Acta Biochimica et Biophysica Sinica	2023
A narrative review of the role of HDAC6 in idiopathic pulmonary fibrosis Yu H, Liu S, Wang S, Gu X	Journal of Thoracic Disease	2023
The role of proteasomes in tumorigenesis Zhou X, Xu R, Wu Y, Zhou L, Xiang T	Genes & Diseases	2023
Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma Lu Y, Yang J, Zhu J, Shu Y, Zou X, Ruan Q, Luo S, Wang Y, Wen J	Journal of Oncology	2023
Interaction of Immune and Cancer Cells M Klink, I Szulc-Kielbik		2022
Human iPSC-Cardiomyocytes as an Experimental Model to Study Epigenetic Modifiers of Electrophysiology M Pozo, G Meredith, E Entcheva	Cells	2022
How to Slow down the Ticking Clock: Age-Associated Epigenetic Alterations and Related Interventions to Extend Life Span A Galow, S Peleg	Cells	2022
The paradigm of drug resistance in cancer: an epigenetic perspective S Adhikari, A Bhattacharya, S Adhikary, V Singh, S Gadad, S Roy, C Das	Bioscience Reports	2022
Cancer Stem Cells in Ovarian Cancer—A Source of Tumor Success and a Challenging Target for Novel Therapies J Wilczyński, M Wilczyński, E Paradowska	International journal of molecular sciences	2022
HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer Y Zhou, X Jin, H Yu, G Qin, P Pan, J Zhao, T Chen, X Liang, Y Sun, B Wang, D Ren, S Zhu, H Wu	Theranostics	2022
Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain Clauß O, Schäker-Hübner L, Wenzel B, Toussaint M, Deuther-Conrad W, Gündel D, Teodoro R, Dukić-Stefanović S, Ludwig FA, Kopka K, Brust P, Hansen FK, Scheunemann M	Pharmaceuticals	2022
Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer Barbier C, Mansour A, Ismailova A, Sarmadi F, Scarlata DA, Bouttier M, Zeitouni C, Wang C, Gleason JL, White JH	Scientific Reports	2022
Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD+ AML Cells Feng P, Zhang J, Zhang J, Liu X, Pan L, Chen D, Ji M, Lu F, Li P, Li G, Sun T, Li J, Ye J, Ji C	Frontiers in Cell and Developmental Biology	2022
Anti-Colon Cancer Activity of Novel Peptides Isolated from In Vitro Digestion of Quinoa Protein in Caco-2 Cells Fan X, Guo H, Teng C, Zhang B, Blecker C, Ren G	Foods	2022
MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis Du L, Wang D, Wei X, Liu C, Xiao Z, Qian W, Song Y, Hou X	BMC Gastroenterology	2022
Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor Sundaramurthi H, García-Mulero S, Tonelotto V, Slater K, Marcone S, Piulats JM, Watson RW, Tobin DJ, Jensen LD, Kennedy BN	Cancers	2022
HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma Gong W, Wang L, Schubert ML, Kleist C, Neuber B, Wang S, Yang M, Hückelhoven-Krauss A, Wu D, Schmitt A, Müller-Tidow C, Shiku H, Schmitt M, Sellner L	Biomedicines	2022
LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression Xu X, Ding P, Shi L, Wu G, Ma X	BMC Cancer	2022
Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein Manna PR, Ahmed AU, Molehin D, Narasimhan M, Pruitt K, Reddy PH	Biomedicines	2022
Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma Xu Y, Liao W, Luo Q, Yang D, Pan M	Frontiers in immunology	2022
Upregulation of p75NTR by Histone Deacetylase Inhibitors Sensitizes Human Neuroblastoma Cells to Targeted Immunotoxin-Induced Apoptosis Dedoni S, Olianas A, Manconi B, Collu M, Tuveri B, Vincis ME, Olianas MC, Onali P	International journal of molecular sciences	2022
Synthesis of potent and selective HDAC6 inhibitors led to unexpected opening of a quinazoline ring Moi D, Citarella A, Bonanni D, Pinzi L, Passarella D, Silvani A, Giannini C, Rastelli G	RSC Advances	2022
Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors Wang S, Han S, Cheng W, Miao R, Li S, Tian X, Kan Q	Drug design, development and therapy	2022
Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors. Sedky NK, Hamdan AA, Emad S, Allam AL, Ali M, Tolba MF	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2022
Untargeted LC-MS/MS Metabolomics Study on the MCF-7 Cell Line in the Presence of Valproic Acid. Estrada-Pérez AR, Rosales-Hernández MC, García-Vázquez JB, Bakalara N, Fromager B, Correa-Basurto J	International journal of molecular sciences	2022
The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements via Epigenetic Modification. Yao J, Li G, Cui Z, Chen P, Wang J, Hu Z, Zhang L, Wei L	Frontiers in pharmacology	2022
Classification models and SAR analysis on HDAC1 inhibitors using machine learning methods. Li R, Tian Y, Yang Z, Ji Y, Ding J, Yan A	Molecular Diversity	2022
Three-dimensional quantitative structural-activity relationship and molecular dynamics study of multivariate substituted 4-oxyquinazoline HDAC6 inhibitors. Zhao L, Fu L, Li G, Yu Y, Wang J, Liang H, Shu M, Lin Z, Wang Y	Molecular Diversity	2022
Glucose Starvation Induces a Switch in the Histone Acetylome for Activation of Gluconeogenic and Fat Metabolism Genes Hsieh WC, Sutter BM, Ruess H, Barnes SD, Malladi VS, Tu BP	Molecular Cell	2022
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer Bag A, Schultz A, Bhimani S, Stringfield O, Dominguez W, Mo Q, Cen L, Adeegbe D	OncoImmunology	2022
HDAC Inhibitory and Anti-Cancer Activities of Curcumin and Curcumin Derivative CU17 against Human Lung Cancer A549 Cells Namwan N, Senawong G, Phaosiri C, Kumboonma P, Somsakeesit LO, Samankul A, Leerat C, Senawong T	Molecules (Basel, Switzerland)	2022
Glioblastoma: Current Status, Emerging Targets, and Recent Advances Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K, Liou JP	Journal of Medicinal Chemistry	2022
Effect of AR42 in Primary Vestibular Schwannoma Cells and a Xenograft Model of Vestibular Schwannoma Misztal C, Bracho O, Bas E, Estivill M, Ivan ME, Morcos J, Bhatia R, Telischi F, Liu XZ, Gultekin SH, Fernandez-Valle C, Dinh CT	Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology	2022
The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer. You Q, Wang J, Yu Y, Li F, Meng L, Chen M, Yang Q, Xu Z, Sun J, Zhuo W, Chen Z	Apoptosis : an international journal on programmed cell death	2022
Differential molecular mechanistic behavior of HDACs in cancer progression. Singh T, Kaur P, Singh P, Singh S, Munshi A	Medical Oncology	2022
Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma Lu X, Liu M, Yang J, Que Y, Zhang X	Clinical & Experimental Immunology	2022
Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. Pramanik SD, Kumar Halder A, Mukherjee U, Kumar D, Dey YN, R M	Frontiers in Chemistry	2022
Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy Ren X, Li T, Zhang W, Yang X	Cells	2022
Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs Sabit H, Abdel-Hakeem M, Shoala T, Abdel-Ghany S, Abdel-Latif MM, Almulhim J, Mansy M	Pharmaceutics	2022
Tackling Microbial Resistance with Isatin-Decorated Thiazole Derivatives: Design, Synthesis, and in vitro Evaluation of Antimicrobial and Antibiofilm Activity Kassab RM, Al-Hussain SA, Elleboudy NS, Albohy A, Zaki ME, Abouzid KA, Muhammad ZA	Drug design, development and therapy	2022
Heme oxygenase 1 overexpression induces immune evasion of acute myeloid leukemia against natural killer cells by inhibiting CD48 Zhang T, Fang Q, Liu P, Wang P, Feng C, Wang J	Journal of Translational Medicine	2022
Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. Kawakubo K, Castillo CF, Liss AS	Journal of Gastroenterology	2022
Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells Zhao M, Duan Y, Wang J, Liu Y, Zhao Y, Wang H, Zhang L, Chen ZS, Hu Z, Wei L	Journal of Oncology	2022
Primary cilium in kidney development, function and disease. Bai Y, Wei C, Li P, Sun X, Cai G, Chen X, Hong Q	Frontiers in Endocrinology	2022
Evidence that HDAC7 Acts as an Epigenetic “Reader” of AR Acetylation through NCoR-HDAC3 Dissociation Zhang Y, Andrade R, Hanna AA, Pflum MK	Cell Chemical Biology	2022
Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression Wang J, Li J, Zhang X, Zhang M, Hu X, Yin H	Frontiers in Molecular Biosciences	2022
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P, Tonelli R	Cancers	2022
Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer Han R, Yang H, Li Y, Ling C, Lu L	Medical Oncology	2022
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways Zhu Z, McGray AJ, Jiang W, Lu B, Kalinski P, Guo ZS	Molecular Cancer	2022
Small molecule inhibitors targeting the cancers Liu G, Chen T, Zhang X, Ma X, Shi H		2022
CREPT Disarms the Inhibitory Activity of HDAC1 on Oncogene Expression to Promote Tumorigenesis Cao Y, Ning B, Tian Y, Lan T, Chu Y, Ren F, Wang Y, Meng Q, Li J, Jia B, Chang Z	Cancers	2022
TMP195 Exerts Antitumor Effects on Colorectal Cancer by Promoting M1 Macrophages Polarization Han Y, Sun J, Yang Y, Liu Y, Lou J, Pan H, Yao J, Han W	International journal of biological sciences	2022
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors. Diamond JR, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, Bagby SM, Pafford J, Yacob BW, Newton TP, Tentler JJ, Gittleman B, Hartman SJ, DeMattei JA, Winkler JD, Wendt MK, Schiemann WP, Eckhardt SG, Liu X, Piscopio AD	Molecular cancer therapeutics	2022
新型Ⅰ类和Ⅱb类选择性HDAC抑制剂甲磺酸普依司他治疗弥漫大B细胞淋巴瘤的体外药效学和作用机制研究		2022
Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies Markouli M, Strepkos D, Piperi C	International journal of molecular sciences	2022
Modified Suberoylanilide Hydroxamic Acid Reduced Drug-Associated Immune Cell Death and Organ Damage under Lipopolysaccharide Inflammatory Challenge Truong N, Goodis CC, Cottingham AL, Shaw JR, Fletcher S, Pearson RM		2022
DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro Kwesi-Maliepaard EM, Malik M, van Welsem T, van Doorn R, Vermeer MH, Vlaming H, Jacobs H, van Leeuwen F	Frontiers in Genetics	2022
Protein acylation: mechanisms, biological functions and therapeutic targets. Shang S, Liu J, Hua F	Signal Transduction and Targeted Therapy	2022
Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death Jenkins LJ, Luk IY, Fairlie WD, Lee EF, Palmieri M, Schoffer KL, Tan T, Ng I, Vukelic N, Tran S, Tse JW, Nightingale R, Alam Z, Chionh F, Iatropoulos G, Ernst M, Afshar-Sterle S, Desai J, Gibbs P, Sieber OM, Dhillon AS, Tebbutt NC, Mariadason JM	Molecular cancer therapeutics	2022
Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine Lee YT, Tan YJ, Oon CE	Acta pharmaceutica Sinica. B	2022
Harnessing anti‐tumor and tumor‐tropism functions of macrophages via nanotechnology for tumor immunotherapy Zheng Y, Han Y, Sun Q, Li Z		2022
Targeting epigenetic alterations in cancer stem cells F. V, V. D. P, C. M, M. LI, C. D, G. P, D. C, A. T, M. G, S. DF, M. T, V. V, G. S		2022
Understanding Myocardial Metabolism in the Context of Cardio-Oncology Liu J, Chen ZZ, Patel J, Asnani A	Heart failure clinics	2022
Entinostat Induces Anti-tumor Immune Responses Through Immune Editing of Tumor Neoantigens Andrew Truong, Mi Zhou, Bhavani Krishnan, Takanobu Utsumi, Ujjawal Manocha, Kyle G. Stewart, Wolfgang Beck, Tracy L. Rose, Matthew Milowsky, Xiaping He, Christof C. Smith, Lisa Bixby, Charles Perou, Sara E Wobker, Sean T. Bailey, Benjamin G. Vincent, William Y. Kim	Journal of Clinical Investigation	2021
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma M Hirano, Y Imai, Y Kaito, T Murayama, K Sato, T Ishida, J Yamamoto, T Ito, M Futami, M Ri, H Yasui, T Denda, Y Tanaka, Y Ota, M Nojima, Y Kamikubo, N Gotoh, S Iida, H Handa, A Tojo	Journal of Experimental & Clinical Cancer Research	2021
HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer ME Clements, L Holtslander, C Edwards, V Todd, SD Dooyema, K Bullock, K Bergdorf, CA Zahnow, RM Connolly, RW Johnson	Oncogene	2021
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer M Li, S Viswanadhapalli, B Santhamma, UP Pratap, Y Luo, J Liu, KA Altwegg, W Tang, Z Liu, X Li, B Ebrahimi, H Yan, Y Zou, S Konda, GR Sareddy, Z Xu, Y Chen, MK Rao, AJ Brenner, VG Kaklamani, RR Tekmal, G Ahmed, GV Raj, KJ Nickisch, HB Nair, RK Vadlamudi	Communications biology	2021
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy E Dai, Z Zhu, S Wahed, Z Qu, WJ Storkus, ZS Guo	Molecular Cancer	2021
Targeting the acetylation signaling pathway in cancer therapy F Dang, W Wei	Seminars in Cancer Biology	2021
The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus S Dewanjee, J Vallamkondu, RS Kalra, P Chakraborty, M Gangopadhyay, R Sahu, V Medala, A John, PH Reddy, VD Feo, R Kandimalla	Cells	2021
Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma HM Torres, AM VanCleave, M Vollmer, DL Callahan, A Smithback, JM Conn, T Rodezno-Antunes, Z Gao, Y Cao, Y Afeworki, J Tao	Cancers	2021
Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis SH Soliman, A Orlacchio, F Verginelli	Microorganisms	2021
The Neurotrophin Receptor TrkC as a Novel Molecular Target of the Antineuroblastoma Action of Valproic Acid S Dedoni, L Marras, MC Olianas, A Ingianni, P Onali	International journal of molecular sciences	2021
Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma C Lanzi, E Favini, LD Bo, M Tortoreto, N Arrighetti, N Zaffaroni, G Cassinelli	Journal of Experimental & Clinical Cancer Research	2021
SNAIL1: Linking Tumor Metastasis to Immune Evasion X Tang, X Sui, L Weng, Y Liu	Frontiers in immunology	2021
Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities WH Talib, AI Mahmod, A Kamal, HM Rashid, AM Alashqar, S Khater, D Jamal, M Waly	Current issues in molecular biology	2021
Differential profiles of HDAC1 substrates and associated proteins in breast cancer cells revealed by trapping Y Zhang, DA Nalawansha, KE Herath, R Andrade, MK Pflum		2021
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma S Okabe, Y Tanaka, A Gotoh	Experimental Hematology and Oncology	2021
A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo YW Wu, MW Chao, HJ Tu, LC Chen, KC Hsu, JP Liou, CR Yang, SC Yen, WC HuangFu, SL Pan	Oncogenesis	2021
Vorinostat ameliorates IL‐1α‐induced reduction of type II collagen by inhibiting the expression of ELF3 in chondrocytes X Miao, Y Wu, P Wang, Q Zhang, C Zhou, X Yu, L Cao	Journal of Biochemical and Molecular Toxicology	2021
Immune modulation underpins the anti‐cancer activity of HDAC inhibitors W Blaszczak, G Liu, H Zhu, W Barczak, A Shrestha, G Albayrak, S Zheng, D Kerr, A Samsonova, NB Thangue	Molecular Oncology	2021
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies MB Garcia-Fabiani, S Haase, A Comba, S Carney, B McClellan, K Banerjee, MS Alghamri, F Syed, P Kadiyala, FJ Nunez, M Candolfi, A Asad, N Gonzalez, ME Aikins, A Schwendeman, JJ Moon, PR Lowenstein, MG Castro	Frontiers in Oncology	2021
PPAR-α Hypermethylation in the Hippocampus of Mice Exposed to Social Isolation Stress Is Associated with Enhanced Neuroinflammation and Aggressive Behavior F Matrisciano, G Pinna	International journal of molecular sciences	2021
Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma M Müller, L Rösch, S Najafi, C Gatzweiler, J Ridinger, XF Gerloff, DT Jones, J Baßler, S Kreth, S Stainczyk, K Frese, B Meder, F Westermann, T Milde, H Peterziel, O Witt, I Oehme	Cancers	2021
Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia X Jiang, L Jiang, J Cheng, F Chen, J Ni, C Yin, Q Wang, Z Wang, D Fang, Z Yi, G Yu, Q Zhong, BZ Carter, F Meng	Journal of Translational Medicine	2021
Epigenetic reprogramming during prostate cancer progression: A perspective from development S Goel, V Bhatia, T Biswas, B Ateeq	Seminars in Cancer Biology	2021
Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat LO Afolabi, J Bi, X Li, AO Adeshakin, FO Adeshakin, H Wu, D Yan, L Chen, X Wan	Frontiers in immunology	2021
Targeting mutant p53 for cancer therapy: direct and indirect strategies J Hu, J Cao, W Topatana, S Juengpanich, S Li, B Zhang, J Shen, L Cai, X Cai, M Chen	Journal of Hematology & Oncology	2021
Characterization of Histone Deacetylase Mechanisms in Cancer Development R Hai, L He, G Shu, G Yin	Frontiers in Oncology	2021
Epigenetic reprogramming enhances the therapeutic efficacy of osteoblast‐derived extracellular vesicles to promote human bone marrow stem cell osteogenic differentiation K Man, MY Brunet, M FernandezRhodes, S Williams, LM Heaney, LA Gethings, A Federici, OG Davies, D Hoey, SC Cox	Journal of Extracellular Vesicles	2021
The H3K36me2 methyltransferase NSD1 modulates H3K27ac at active enhancers to safeguard gene expression Y Fang, Y Tang, Y Zhang, Y Pan, J Jia, Z Sun, W Zeng, J Chen, Y Yuan, D Fang	Nucleic Acids Research	2021
Polo-Like Kinase 4’s Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy X Zhang, C Wei, H Liang, L Han	Frontiers in Oncology	2021
Correlation analysis between expression of histone deacetylase 6 and clinical parameters in IgA nephropathy patients Y Hu, M Shang, Y Shi, M Tao, W Yuan, L Tang, X Ma, B Cui, H Chen, X Zhou, S Zhuang, N Liu	Renal Failure	2021
Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape L Sadeghi, AP Wright	International journal of molecular sciences	2021
TET2 Inhibits PD-L1 Gene Expression in Breast Cancer Cells through Histone Deacetylation Y Shen, L Liu, M Wang, B Xu, R Lyu, YG Shi, L Tan	Cancers	2021
An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality S Mueller, G Dennison, S Liu	International journal of environmental research and public health	2021
Epigenetic Mechanisms of HIV-1 Persistence R Verdikt, O Hernalsteens, CV Lint	Human vaccines	2021
Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article A Bobin, C Gruchet, S Guidez, H Gardeney, LN Makunza, M Vonfeld, A Lévy, L Cailly, F Sabirou, T Systchenko, N Moya, X Leleu	Cancers	2021
Recent Discoveries in Epigenetic Modifications of Polycystic Kidney Disease SA Bowden, EJ Rodger, A Chatterjee, MR Eccles, C Stayner	International journal of molecular sciences	2021
Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy O Tatli, GD Doganay	Molecules (Basel, Switzerland)	2021
Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy M Zhang, L Gao, Y Ye, X Li	Investigational New Drugs	2021
Repression of the miR-627-5p by histone deacetylase 3 contributes to hypoxia-induced hepatocellular carcinoma progression J Wang, R Liu, Y Wang, H Mo, Y Niu, Q Xu, Q Liu	Journal of Cancer	2021
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat Wu CP, Hung CY, Lusvarghi S, Chang YF, Hsiao SH, Huang YH, Hung TH, Yu JS, Ambudkar SV	International journal of molecular sciences	2021
A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo Yan Z, Zhang K, Ji M, Xu H, Chen X	Frontiers in pharmacology	2021
Genetic screen for suppressors of increased silencing in rpd3 mutants in Saccharomyces cerevisiae identifies a potential role for H3K4 methylation Kleinschmidt RA, Lyon LM, Smith SL, Rittenberry J, Lawless KM, Acosta AA, Donze D	G3: Genes\|Genomes\|Genetics	2021
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma Zhong M, Tan J, Pan G, Jiang Y, Zhou H, Lai Q, Chen Q, Fan L, Deng M, Xu B, Zha J	Frontiers in Oncology	2021
HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases Shanmugam G, Rakshit S, Sarkar K	Translational oncology	2021
Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer Tarasenko N, Wilner HJ, Nudelman A, Kessler-Icekson G, Rephaeli A	Pharmaceuticals	2021
HDAC6 Substrate Discovery Using Proteomics-Based Substrate Trapping: HDAC6 Deacetylates PRMT5 to Influence Methyltransferase Activity Gomes ID, Ariyaratne UV, Pflum MK	ACS chemical biology	2021
Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models Yun HJ, Kim HJ, Kim J, Kim SY, Chang HS, Park CS, Chang HJ, Park KC	International journal of molecular sciences	2021
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma Streubel G, Schrepfer S, Kallus H, Parnitzke U, Wulff T, Hermann F, Borgmann M, Hamm S	Scientific Reports	2021
CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis Bae D, Lee JY, Ha N, Park J, Baek J, Suh D, Lim HS, Ko SM, Kim T, Som Jeong D, Son WC	Scientific Reports	2021
Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas Wang J, Elkrief A, Guo W, Shukla N, Gounder M, Ladanyi M	Sarcoma	2021
Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma Xiao L, Somers K, Murray J, Pandher R, Karsa M, Ronca E, Bongers A, Terry R, Ehteda A, Gamble LD, Issaeva N, Leonova KI, O\u2019Connor A, Mayoh C, Venkat P, Quek H, Brand J, Kusuma FK, Pettitt JA, Mosmann E, Kearns A, Eden G, Alfred S, Allan S, Zhai L, Kamili A, Gifford AJ, Carter DR, Henderson MJ, Fletcher JI, Marshall G, Johnstone RW, Cesare AJ, Ziegler DS, Gudkov AV, Gurova KV, Norris MD, Haber M	Clinical cancer research	2021
Effect of Decitabine (5-aza-2ˈ-deoxycytidine, 5-aza-CdR) in Comparison with Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) on DNMT1, DNMT3a and DNMT3b, HDAC 1-3, SOCS 1, SOCS 3, JAK2, and STAT3 Gene Expression in Hepatocellular Carcinoma HLE and LCL-PI 11 Cell Lines Sanaei M, Kavoosi F, Pourahmadi M	Asian Pacific Journal of Cancer Prevention	2021
Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Wang CY, Chao YJ, Chen YL, Wang TW, Phan NN, Hsu HP, Shan YS, Lai MD	International journal of medical sciences	2021
Downregulation of Mcl-1 by Panobinostat Potentiates Proton Beam Therapy in Hepatocellular Carcinoma Cells Choi C, Lee GH, Son A, Yoo GS, Yu JI, Park HC	Cells	2021
An unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation Cao Z, Kon N, Liu Y, Xu W, Wen J, Yao H, Zhang M, Wu Z, Yan X, Zhu WG, Gu W, Wang D	Science Advances	2021
Histone deacetylase-2: A potential regulator and therapeutic target in liver disease (Review) Liu YR, Wang JQ, Huang ZG, Chen RN, Cao X, Zhu DC, Yu HX, Wang XR, Zhou HY, Xia Q, Li J	International journal of molecular medicine	2021
Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application Canberk S, Lima AR, Pinto M, Soares P, Máximo V	Frontiers in Endocrinology	2021
Imidazoles as Potential Anticancer Agents: An Update on Recent Studies Sharma P, LaRosa C, Antwi J, Govindarajan R, Werbovetz KA	Molecules (Basel, Switzerland)	2021
Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy Xiao W, Zhou Q, Wen X, Wang R, Liu R, Wang T, Shi J, Hu Y, Hou J	Frontiers in pharmacology	2021
Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis Du J, Han X, Lin S, Qiu C, Zhu L, Huang Z, Hou J	Frontiers in Medicine	2021
Exploring novel capping framework: high substituent pyridine-hydroxamic acid derivatives as potential antiproliferative agents Hernández-Borja F, Mercado-Sánchez I, Alcaraz Y, García-Revilla MA, Villegas Gómez C, Ordaz-Rosado D, Santos-Martínez N, García-Becerra R, Vazquez MA	DARU Journal of Pharmaceutical Sciences	2021
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Quinn DI, Tsao-Wei DD, Twardowski P, Aparicio AM, Frankel P, Chatta G, Wright JJ, Groshen SG, Khoo S, Lenz HJ, Lara PN, Gandara DR, Newman E	Investigational New Drugs	2021
Small-molecule inhibitors of histone deacetylase improve CRISPR-based adenine base editing. Shin HR, See JE, Kweon J, Kim HS, Sung GJ, Park S, Jang AH, Jang G, Choi KC, Kim I, Kim JS, Kim Y	Nucleic Acids Research	2021
Novel 4-Oxoquinazoline-Based N-Hydroxypropenamides as Histone Deacetylase Inhibitors: Design, Synthesis, and Biological Evaluation. Anh DT, Hai PT, Huy LD, Ngoc HB, Ngoc TTM, Dung DTM, Park EJ, Song IK, Kang JS, Kwon JH, Tung TT, Han SB, Nam NH	ACS Omega	2021
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gupta VG, Hirst J, Petersen S, Roby KF, Kusch M, Zhou H, Clive ML, Jewell A, Pathak HB, Godwin AK, Wilson AJ, Crispens MA, Cybulla E, Vindigni A, Fuh KC, Khabele D	Gynecologic Oncology	2021
Requirement of Histone Deacetylase 6 for Interleukin-6 Induced Epithelial-Mesenchymal Transition, Proliferation, and Migration of Peritoneal Mesothelial Cells. Shi Y, Tao M, Ni J, Tang L, Liu F, Chen H, Ma X, Hu Y, Zhou X, Qiu A, Zhuang S, Liu N	Frontiers in pharmacology	2021
ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Park SJ, Joo SH, Lee N, Jang WJ, Seo JH, Jeong CH	Archives of Pharmacal Research	2021
HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies Slaughter MJ, Shanle EK, Khan A, Chua KF, Hong T, Boxer LD, Allis CD, Josefowicz SZ, Garcia BA, Rothbart SB, Strahl BD, Davis IJ	Cell Reports	2021
Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia S Kim, S Santhanam, S Lim, J Choi	International journal of molecular sciences	2020
Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors M Ge, D Li, Z Qiao, Y Sun, T Kang, S Zhu, S Wang, H Xiao, C Zhao, S Shen, Z Xu, H Liu	Oncogene	2020
Targeting the epigenetic regulation of antitumour immunity SJ Hogg, PA Beavis, MA Dawson, RW Johnstone	Nature Reviews Drug Discovery	2020
Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease LA Kulka, PV Fangmann, D Panfilova, H Olzscha	Frontiers in Cell and Developmental Biology	2020
Enhancing venetoclax activity in hematological malignancies T Satta, S Grant	Expert Opinion on Investigational Drugs	2020
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy G Li, Y Tian, WG Zhu	Frontiers in Cell and Developmental Biology	2020
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis AT Kuykendall, NP Horvat, G Pandey, R Komrokji, GW Reuther	Cancers	2020
Givinostat: an emerging treatment for polycythemia vera HT Chifotides, P Bose, S Verstovsek	Expert Opinion on Investigational Drugs	2020
Bifunctional HDAC Therapeutics: One Drug to Rule Them All? JP Smalley, SM Cowley, JT Hodgkinson	Molecules (Basel, Switzerland)	2020
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells H Wang, C Fu, J Du, H Wang, R He, X Yin, H Li, X Li, H Wang, K Li, L Zheng, Z Liu, Y Qiu	Journal of Experimental & Clinical Cancer Research	2020
Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives V Buocikova, I Rios-Mondragon, E Pilalis, A Chatziioannou, S Miklikova, M Mego, K Pajuste, M Rucins, NE Yamani, EM Longhin, A Sobolev, M Freixanet, V Puntes, A Plotniece, M Dusinska, MR Cimpan, A Gabelova, B Smolkova	Cancers	2020
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs Y Xiao, J Wang, LY Zhao, X Chen, G Zheng, X Zhang, D Liao	Chemical Communications	2020
Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells S Zhang, Y Gong, C Li, W Yang, L Li	Cell Proliferation	2020
Targeting the immune milieu in gastrointestinal cancers F Turkes, J Mencel, N Starling	Journal of Gastroenterology	2020
Cell Cycle Regulation in Macrophages and Susceptibility to HIV-1 IA Ferreira, JZ Porterfield, RK Gupta, P Mlcochova	Viruses	2020
CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma Y Chang, YB Lee, EJ Cho, JH Lee, SJ Yu, YJ Kim, JH Yoon	BMC Cancer	2020
Targeting the photoreceptor cilium for the treatment of retinal diseases J Ran, J Zhou	Acta Pharmacologica Sinica	2020
Targeting NAD + Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance EP Jane, DR Premkumar, S Thambireddy, B Golbourn, S Agnihotri, KC Bertrand, SC Mack, MI Myers, A Chattopadhyay, DL Taylor, ME Schurdak, AM Stern, IF Pollack	Molecular cancer research : MCR	2020
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma P Zhang, M Zhang	Clinical Epigenetics	2020
Epigenetic Aberrations in Multiple Myeloma C Caprio, A Sacco, V Giustini, AM Roccaro	Cancers	2020
ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer G Huang, ST Pan	Oxidative medicine and cellular longevity	2020
Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction B Burke, C Eden, C Perez, A Belshoff, S Hart, L Plaza-Rojas, MD Reyes, K Prajapati, C Voelkel-Johnson, E Henry, G Gupta, J Guevara-Patiño	Frontiers in Oncology	2020
Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts JK Wrobel, S Najafi, S Ayhan, C Gatzweiler, D Krunic, J Ridinger, T Milde, F Westermann, H Peterziel, B Meder, M Distel, O Witt, I Oehme	Pharmaceuticals (Basel, Switzerland)	2020
Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets KM Arif, EK Elliott, LM Haupt, LR Griffiths	Cancers	2020
Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2 N Bora-Singhal, D Mohankumar, B Saha, CM Colin, JY Lee, MW Martin, X Zheng, D Coppola, S Chellappan	Scientific Reports	2020
Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach K Ranganna, C Selvam, A Shivachar, Z Yousefipour	International journal of molecular sciences	2020
Prostate cancer cell‐intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone KL Owen, LJ Gearing, DJ Zanker, NK Brockwell, WH Khoo, DL Roden, M Cmero, S Mangiola, MK Hong, AJ Spurling, M McDonald, CL Chan, A Pasam, RJ Lyons, HM Duivenvoorden, A Ryan, LM Butler, JM Mariadason, TG Phan, VM Hayes, S Sandhu, A Swarbrick, NM Corcoran, PJ Hertzog, PI Croucher, C Hovens, BS Parker	EMBO reports	2020
Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer. Sasidharan Nair V, Saleh R, Toor SM, Taha RZ, Ahmed AA, Kurer MA, Murshed K, Alajez NM, Abu Nada M, Elkord E	Clinical Epigenetics	2020
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ	Haematologica	2020
RcLS2F – A Novel Fungal Class 1 KDAC Co-repressor Complex in Aspergillus nidulans Bauer I, Gross S, Merschak P, Kremser L, Karahoda B, Bayram ÖS, Abt B, Binder U, Gsaller F, Lindner H, Bayram Ö, Brosch G, Graessle S	Frontiers in microbiology	2020
LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression Wang Z, Yu W, Qiang Y, Xu L, Ma F, Ding P, Shi L, Chang W, Mei Y, Ma X		2020
Protein acetylation derepresses Serotonin Synthesis to potentiate Pancreatic Beta-Cell Function through HDAC1-PKA-Tph1 signaling Zhang Y, Wang S, Zhang L, Zhou F, Zhu K, Zhu Q, Liu Q, Liu Y, Jiang L, Ning G, Bi Y, Zhou L, Wang X	Theranostics	2020
Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6 Osko JD, Christianson DW	Acta Crystallographica Section F Structural Biology Communications	2020
Early Life Stress- and Drug-Induced Histone Modifications Within the Ventral Tegmental Area Shepard RD, Nugent FS	Frontiers in Cell and Developmental Biology	2020
Distinct contributions of DNA methylation and histone acetylation to the genomic occupancy of transcription factors Cusack M, King HW, Spingardi P, Kessler BM, Klose RJ, Kriaucionis S	Genome research	2020
Addressing the Possibility of a Histone-Like Code in Bacteria Carabetta VJ	Journal of Proteome Research	2020
Molecular Docking Simulations on Histone Deacetylases (HDAC)-1 and -2 to Investigate the Flavone Binding Scafuri B, Bontempo P, Altucci L, De Masi L, Facchiano A	Biomedicines	2020
Impact of histone methyltransferase SUV420H2 in breast cancer Isin H, Özgür E, Talu CK, Trabulus DC, Karaçetin D, Gezer U	Biomedical Reports	2020
LncRNA NEAT1/miR-129/Bcl-2 signaling axis contributes to HDAC inhibitor tolerance in nasopharyngeal cancer Xue F, Cheng Y, Xu L, Tian C, Jiao H, Wang R, Gao X	Aging	2020
Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer Lian B, Pei YC, Jiang YZ, Xue MZ, Li DQ, Li XG, Zheng YZ, Liu XY, Qiao F, Sun WL, Ling H, He M, Yao L, Hu X, Shao ZM	Theranostics	2020
SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression Zhang Z, Qiu N, Yin J, Zhang J, Liu H, Guo W, Liu M, Liu T, Chen D, Luo K, Li H, He Z, Liu J, Zheng G	Theranostics	2020
Design and synthesis of diazine-based panobinostat analogues for HDAC8 inhibition Balasubramaniam S, Vijayan S, Goldman LV, May XA, Dodson K, Adhikari S, Rivas F, Watkins DL, Stoddard SV	Beilstein Journal of Organic Chemistry	2020
HDAC7 promotes the oncogenicity of nasopharyngeal carcinoma cells by miR-4465-EphA2 signaling axis Li QG, Xiao T, Zhu W, Yu ZZ, Huang XP, Yi H, Lu SS, Tang YY, Huang W, Xiao ZQ	Cell Death and Disease	2020
Lysine acetylation as drug target in fungi: an underexplored potential in Aspergillus spp. Wassano NS, Leite AB, Reichert-Lima F, Schreiber AZ, Moretti NS, Damasio A	Brazilian Journal of Microbiology	2020
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors Thakur A, Tawa GJ, Henderson MJ, Danchik C, Liu S, Shah P, Wang AQ, Dunn G, Kabir M, Padilha EC, Xu X, Simeonov A, Kharbanda S, Stone R, Grewal G	Journal of Medicinal Chemistry	2020
Trichostatin A regulates fibro/adipogenic progenitor adipogenesis epigenetically and reduces rotator cuff muscle fatty infiltration Liu X, Liu M, Lee L, Davies M, Wang Z, Kim H, Feeley BT	Journal of orthopaedic research : official publication of the Orthopaedic Research Society	2020
The Case for Enzymatic Competitive Metal Affinity Methods Reilley DJ, Hennefarth MR, Alexandrova AN	ACS Catalysis	2020
Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial membrane potential disruption in neuroblastoma cells. Kommalapati VK, Kumar D, Tangutur AD	Molecular and Cellular Biochemistry	2020
Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma. Mitsiogianni M, Trafalis DT, Franco R, Zoumpourlis V, Pappa A, Panayiotidis MI	European Journal of Nutrition	2020
Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors. Bobrowicz M, Slusarczyk A, Domagala J, Dwojak M, Ignatova D, Chang YT, Iselin C, Miazek-Zapala N, Marhelava K, Guenova E, Winiarska M	Oncology Letters	2020
Inhibition of Histone Methyltransferase EZH2 Suppresses Endometriotic Vesicle Development in a Rat Model of Endometriosis. Seguinot-Tarafa I, Luna N, Suarez E, Appleyard CB, Flores I	Reproductive sciences (Thousand Oaks, Calif.)	2020
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs) Luo Y, Li H	International journal of molecular sciences	2020
A C21-steroidal derivative suppresses T-cell lymphoma in mice by inhibiting SIRT3 via SAP18-SIN3 Gajendran B, Varier KM, Liu W, Wang C, Sample KM, Zacksenhaus E, Juiwei C, Huang L, Hao X, Ben-David Y		2020
Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance Ge M, Qiao Z, Kong Y, Liang H, Sun Y, Lu H, Xu Z, Liu H	British Journal of Cancer	2020
Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer Li Y, Liu Y, Zhao N, Yang X, Li Y, Zhai F, Zang X, Cui W	Cell Death and Disease	2020
The impact of tumour pH on cancer progression: strategies for clinical intervention Ward C, Meehan J, Gray ME, Murray AF, Argyle DJ, Kunkler IH, Langdon SP		2020
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma VG Ramakrishnan, KC Miller, EP Macon, TK Kimlinger, J Haug, S Kumar, WI Gonsalves, SV Rajkumar, SK Kumar	Haematologica	2019
Histone-deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas X Wang, BC Waschke, RA Woolaver, Z Chen, G Zhang, AD Piscopio, X Liu, JH Wang	Cancer immunology research	2019
Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease M Bodas, N Vij	Frontiers in pharmacology	2019
HDAC Inhibitors in Acute Myeloid Leukemia S José-Enériz, GC, Agirre, Prosper	Cancers	2019
A whole organism small molecule screen identifies novel regulators of pancreatic endocrine development CS Helker, ST Mullapudi, LM Mueller, J Preussner, S Tunaru, O Skog, HB Kwon, F Kreuder, JJ Lancman, R Bonnavion, PD Dong, M Looso, S Offermanns, O Korsgren, FM Spagnoli, DY Stainier	Development (Cambridge, England)	2019
Control of viral infections by epigenetic-targeted therapy Z Nehme, S Pasquereau, G Herbein	Clinical Epigenetics	2019
HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis X Lyu, M Hu, J Peng, X Zhang, YY Sanders	Therapeutic Advances in Chronic Disease	2019
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy D Banik, S Moufarrij, A Villagra	International journal of molecular sciences	2019
krCRISPR: an easy and efficient strategy for generating conditional knockout of essential genes in cells B Wang, Z Wang, D Wang, B Zhang, SG Ong, M Li, W Yu, Y Wang	Journal of biological engineering	2019
Hepatic Osteodystrophy—Molecular Mechanisms Proposed to Favor Its Development S Ehnert, RH Aspera-Werz, M Ruoß, S Dooley, JG Hengstler, S Nadalin, B Relja, A Badke, AK Nussler	International journal of molecular sciences	2019
Metabolic Plasticity and Epithelial-Mesenchymal Transition TM Thomson, C Balcells, M Cascante	Journal of Clinical Medicine	2019
In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity SV Stoddard, K Dodson, K Adams, DL Watkins	International journal of molecular sciences	2019
Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies SC Buisman, G de Haan	Cells	2019
Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition PR Manna, AU Ahmed, D Vartak, D Molehin, K Pruitt	Biochemical and Biophysical Research Communications	2019
Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules MV Dannappel, D Sooraj, JJ Loh, R Firestein	Frontiers in Cell and Developmental Biology	2019
Chromatin regulatory mechanisms and therapeutic opportunities in cancer AM Valencia, C Kadoch	Nature Cell Biology	2019
Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma L Zhao, JP Okhovat, EK Hong, YH Kim, GS Wood	Neoplasia (New York, N.Y.)	2019
Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System S Joshi, DL Durden	Journal of Oncology	2019
Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression MC Cleophas, TO Crişan, V Klück, N Hoogerbrugge, RT Netea-Maier, CA Dinarello, MG Netea, LA Joosten	Arthritis Research & Therapy	2019
MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer X Wu, Q Luo, P Zhao, W Chang, Y Wang, T Shu, F Ding, B Li, Z Liu	Proceedings of the National Academy of Sciences	2019
Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases NJ Porter, DW Christianson	Current Opinion in Structural Biology	2019
Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells H Was, SK Krol, D Rotili, A Mai, B Wojtas, B Kaminska, M Maleszewska	Clinical Epigenetics	2019
Isatin and its derivatives: a survey of recent syntheses, reactions, and applications V Varun, S Sonam, R Kakkar	MedChemComm	2019
Antrodia cinnamomea, a Treasured Medicinal Mushroom, Induces Growth Arrest in Breast Cancer Cells, T47D Cells: New Mechanisms Emerge YC Chen, YC Liu, M El-Shazly, TY Wu, JG Chang, YC Wu	International journal of molecular sciences	2019
Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment Z Hu, J Zhou, J Jiang, J Yuan, Y Zhang, X Wei, N Loo, Y Wang, Y Pan, T Zhang, X Zhong, M Long, KT Montone, JL Tanyi, Y Fan, TL Wang, IM Shih, X Hu, L Zhang	Nature Communications	2019
HDAC inhibitors rescue multiple disease-causing CFTR variants F Anglès, DM Hutt, WE Balch	Human Molecular Genetics	2019
Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy W Sun, Y Yi, G Xia, Y Zhao, Y Yu, L Li, C Hua, B He, B Yang, C Yu, C Ye, F Tu, C Chen, X Xu, Z Zheng, W Wang, X Shen	Molecular Therapy	2019
Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway FS Hsu, JT Wu, JY Lin, SP Yang, KL Kuo, WC Lin, CS Shi, PM Chow, SM Liao, CI Pan, JY Hong, HC Chang, KH Huang	International journal of molecular sciences	2019
Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer A Giannopoulou, A Velentzas, E Konstantakou, M Avgeris, S Katarachia, N Papandreou, N Kalavros, V Mpakou, V Iconomidou, E Anastasiadou, I Kostakis, I Papassideri, G Voutsinas, A Scorilas, D Stravopodis	International journal of molecular sciences	2019
Role of Natural Products in Modulating Histone Deacetylases in Cancer M Merarchi, G Sethi, M Shanmugam, L Fan, F Arfuso, K Ahn	Molecules (Basel, Switzerland)	2019
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells J Bhat, S Dubin, A Dananberg, ES Quabius, J Fritsch, CM Dowds, A Saxena, G Chitadze, M Lettau, D Kabelitz	Frontiers in immunology	2019
Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70 P Gong, Y Wang, Y Jing	International journal of molecular sciences	2019
PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors K Shi, X Yin, MC Cai, Y Yan, C Jia, P Ma, S Zhang, Z Zhang, Z Gu, M Zhang, W Di, G Zhuang	eLife	2019
Protein interaction disruption in cancer M Ruffalo, Z Bar-Joseph	BMC Cancer	2019
HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt’s Lymphoma Cells by Impeding the Cell Cycle X Ma, G Xu, Z Li, F Chen, D Wu, J Miao, Y Zhan, Y Fan		2019
IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells GH Kim, SY Choi, TI Oh, SY Kan, H Kang, S Lee, T Oh, HM Ko, JH Lim	International journal of molecular sciences	2019
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action Y Imai, M Hirano, M Kobayashi, M Futami, A Tojo	Cancers	2019
Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer Y Sun, X Bao, Y Ren, L Jia, S Zou, J Han, M Zhao, M Han, H Li, Q Hua, Y Fang, J Yang, C Wu, G Chen, L Wang	Cell Death and Disease	2019
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma SE Kassab, S Mowafy, AM Alserw, JA Seliem, SM El-Naggar, NN Omar, MM Awad	Journal of Enzyme Inhibition and Medicinal Chemistry	2019
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics R Jan, GS Chaudhry	Advanced pharmaceutical bulletin	2019
MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat I Annunziata, D van de Vlekkert, E Wolf, D Finkelstein, G Neale, E Machado, R Mosca, Y Campos, H Tillman, MF Roussel, JA Weesner, LE Fremuth, X Qiu, MJ Han, GC Grosveld, A dAzzo	Nature Communications	2019
Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity N Reßing, V Marquardt, CG Gertzen, A Schöler, A Schramm, T Kurz, H Gohlke, A Aigner, M Remke, FK Hansen	MedChemComm	2019
The epigenome as a putative target for skin repair: the HDAC inhibitor Trichostatin A modulates myeloid progenitor plasticity and behavior and improves wound healing M Cabanel, TP da Costa, MC EL-Cheikh, K Carneiro	Journal of Translational Medicine	2019
N ɛ -acetyl lysine derivatives with zinc binding groups as novel HDAC inhibitors F Wang, C Wang, J Wang, Y Zou, X Chen, T Liu, Y Li, Y Zhao, Y Li, B He	Royal Society Open Science	2019
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L‐dose dependency in HDAC1‐deficient thymic lymphoma H Vlaming, CM McLean, T Korthout, MF Alemdehy, S Hendriks, C Lancini, S Palit, S Klarenbeek, EM KwesiMaliepaard, TM Molenaar, L Hoekman, TT Schmidlin, AF Altelaar, T van Welsem, JH Dannenberg, H Jacobs, F van Leeuwen	The EMBO Journal	2019
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors H Kim, Q Lin, Z Yun	Scientific Reports	2019
BAY 87‑2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK‑3β activation YL Li, MJ Rao, NY Zhang, LW Wu, NM Lin, C Zhang	Experimental and therapeutic medicine	2019
Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors Roca, D Gennaro, Budillon	Journal of Clinical Medicine	2019
Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE N Erdeljac, K Bussmann, A Schöler, FK Hansen, R Gilmour	ACS Medicinal Chemistry Letters	2019
Live Cell Imaging Supports a Key Role for Histone Deacetylase as a Molecular Target during Glioblastoma Malignancy Downgrade through Tumor Competence Modulation A Menezes, GH dos Reis, MC Oliveira-Nunes, F Mariath, M Cabanel, B Pontes, NG Castro, JM de Brito, K Carneiro	Journal of Oncology	2019
Apatinib induces 3‐hydroxybutyric acid production in the liver of mice by peroxisome proliferator‐activated receptor α activation to aid its antitumor effect S Feng, H Wang, Y Wang, R Sun, Y Xie, Z Zhou, H Wang, J Aa, F Zhou, G Wang	Cancer Science	2019
The Histone Deacetylases HosA and HdaA Affect the Phenotype and Transcriptomic and Metabolic Profiles of Aspergillus niger X Li, L Pan, B Wang, L Pan	Toxins	2019
Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer K Xiong, H Zhang, Y Du, J Tian, S Ding	Experimental & molecular medicine	2019
Management of Chronic Myeloid Leukemia in Advanced Phase M Bonifacio, F Stagno, L Scaffidi, M Krampera, FD Raimondo	Frontiers in Oncology	2019
Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells MG Cortiguera, L García-Gaipo, SD Wagner, J León, A Batlle-López, MD Delgado	Scientific Reports	2019
Synthesis of 9-Hydroxystearic Acid Derivatives and Their Antiproliferative Activity on HT 29 Cancer Cells N Calonghi, C Boga, D Telese, S Bordoni, G Sartor, C Torsello, G Micheletti	Molecules (Basel, Switzerland)	2019
Cell signaling and cancer: a mechanistic insight into drug resistance M Panda, BK Biswal	Molecular Biology Reports	2019
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer S Joshi, AR Singh, KX Liu, TV Pham, M Zulcic, D Skola, HB Chun, CK Glass, GA Morales, JR Garlich, DL Durden	Molecular cancer therapeutics	2019
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer JE Gray, A Saltos, T Tanvetyanon, EB Haura, B Creelan, SJ Antonia, M Shafique, H Zheng, W Dai, JJ Saller, Z Chen, N Tchekmedyian, K Goas, R Thapa, TA Boyle, DT Chen, AA Beg	Clinical cancer research	2019
Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2 Y Du, J Lin, R Zhang, W Yang, H Quan, L Zang, Y Han, B Li, H Sun, J Wu	Aging	2019
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis J Laengle, J Kabiljo, L Hunter, J Homola, S Prodinger, G Egger, M Bergmann	Journal for ImmunoTherapy of Cancer	2019
Histone Deacetylases and their Inhibitors in Cancer Epigenetics Hassell	Diseases	2019
Epigenetic modifications of histones in cancer Zhao Z, Shilatifard A	Genome biology	2019
Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer Carafa V, Poziello A, Della Torre L, Giovannelli P, Di Donato M, Safadeh E, Yu Z, Baldi A, Castoria G, Tomaselli D, Mai A, Rotili D, Nebbioso A, Altucci L	International journal of molecular sciences	2019
Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6 Osko JD, Christianson DW	Biochemistry	2019
The Lysine Deacetylase RpdA Is Essential for Virulence in Aspergillus fumigatus Bauer I, Misslinger M, Shadkchan Y, Dietl AM, Petzer V, Orasch T, Abt B, Graessle S, Osherov N, Haas H	Frontiers in microbiology	2019
Methods for the expression, purification, and crystallization of histone deacetylase 6–inhibitor complexes Osko JD, Christianson DW	Methods in enzymology	2019
A comparative study of target engagement assays for HDAC1 inhibitor profiling Asawa RR, Zakharov A, Niehoff T, Chitsaz A, Jadhav A, Henderson MJ, Simeonov A, Martinez NJ		2019
Next-generation of selective histone deacetylase inhibitors Yang F, Zhao N, Ge D, Chen Y	RSC Advances	2019
Quercetin and Sodium Butyrate Synergistically Increase Apoptosis in Rat C6 and Human T98G Glioblastoma Cells Through Inhibition of Autophagy. Taylor MA, Khathayer F, Ray SK	Neurochemical Research	2019
Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity Huang Y, Chen S, Wu S, Dong G, Sheng C	Acta pharmaceutica Sinica. B	2019
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology. Shah RR	Drug Safety	2019
Allyl isothiocyanate regulates lysine acetylation and methylation marks in an experimental model of malignant melanoma. Mitsiogianni M, Mantso T, Trafalis DT, Vasantha Rupasinghe HP, Zoumpourlis V, Franco R, Botaitis S, Pappa A, Panayiotidis MI	European Journal of Nutrition	2019
Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy. Patra S, Panigrahi DP, Praharaj PP, Bhol CS, Mahapatra KK, Mishra SR, Behera BP, Jena M, Bhutia SK	Cellular and molecular life sciences : CMLS	2019
MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF, NRAS, and NF1 mutant melanomas Maertens O, Kuzmickas R, Manchester HE, Emerson CE, Gavin AG, Guild CJ, Wong TC, De Raedt T, Bowman-Colin C, Hatchi E, Garraway LA, Flaherty KT, Pathania S, Elledge SJ, Cichowski K	Cancer Discovery	2019
FMNL1 mediates nasopharyngeal carcinoma cell aggressiveness by epigenetically upregulating MTA1 WH Chen, MY Cai, JX Zhang, FW Wang, LQ Tang, YJ Liao, XH Jin, CY Wang, L Guo, YG Jiang, CP Ren, HQ Mai, MS Zeng, HF Kung, CN Qian, D Xie	Oncogene	2018
Repurposing Pan-HDAC Inhibitors for ARID1A -Mutated Ovarian Cancer T Fukumoto, PH Park, S Wu, N Fatkhutdinov, S Karakashev, T Nacarelli, AV Kossenkov, DW Speicher, S Jean, L Zhang, TL Wang, IM Shih, JR Conejo-Garcia, BG Bitler, R Zhang	Cell Reports	2018
Integrative regulation of physiology by histone deacetylase 3 MJ Emmett, MA Lazar	Nature Reviews Molecular Cell Biology	2018
Placenta growth factor mediated gene regulation in sickle cell disease VK Kalra, S Zhang, P Malik, SM Tahara	Blood Reviews	2018
HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells T Sharif, E Martell, C Dai, MS Ghassemi-Rad, MR Hanes, PJ Murphy, NN Margam, HB Parmar, CA Giacomantonio, R Duncan, PW Lee, S Gujar	Autophagy	2018
Cancer stem cells and tumorigenesis P Zhu, Z Fan	Biophysics Reports	2018
Immune Checkpoint Inhibition in Hodgkin Lymphoma: RH Moy, A Younes		2018
Histone Deacetylase Inhibitors and Diabetic Kidney Disease M Hadden, A Advani	International journal of molecular sciences	2018
CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus EW Choi, JW Song, N Ha, YI Choi, S Kim	Scientific Reports	2018
Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors J Zhang, J Wang, Z Zhou, JE Park, L Wang, S Wu, X Sun, L Lu, T Wang, Q Lin, SK Sze, D Huang, HM Shen	Autophagy	2018
Epigenetic Mechanisms and Hypertension M Liang	Hypertension	2018
Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer T Zhang, J Li, X Ma, Y Yang, W Sun, W Jin, L Wang, Y He, F Yang, Z Yi, Y Hua, M Liu, Y Chen, Z Cai	EBioMedicine	2018
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia M Massimino, S Stella, E Tirrò, C Romano, MS Pennisi, A Puma, L Manzella, A Zanghì, F Stagno, FD Raimondo, P Vigneri	Molecular Cancer	2018
Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells PC Lin, HY Hsieh, PC Chu, C Chen	International journal of molecular sciences	2018
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types KC Hicks, M Fantini, RN Donahue, A Schwab, KM Knudson, SR Tritsch, C Jochems, PE Clavijo, CT Allen, JW Hodge, KY Tsang, J Schlom, SR Gameiro	OncoImmunology	2018
Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus SL Hulin-Curtis, JA Davies, R Jones, E Hudson, L Hanna, JD Chester, AL Parker	Oncotarget	2018
Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors M Daskalakis, D Brocks, YH Sheng, S Islam, A Ressnerova, Y Assenov, T Milde, I Oehme, O Witt, A Goyal, A Kühn, M Hartmann, D Weichenhan, M Jung, C Plass	Cell cycle (Georgetown, Tex.)	2018
Integration of pan-cancer transcriptomics with RPPA proteomics reveals mechanisms of epithelial-mesenchymal transition S Koplev, K Lin, AB Dohlman, A Maayan, J Saez-Rodriguez	PLoS computational biology	2018
Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy A Gutierrez, A Kentsis	British Journal of Haematology	2018
Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 ( SLFN11) expression with class I histone deacetylase inhibitors S Tang, A Thomas, J Murai, J Trepel, SE Bates, VN Rajapakse, Y Pommier	Clinical cancer research	2018
Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition DJ Kim, JM Dunleavey, L Xiao, DW Ollila, MA Troester, CA Otey, W Li, TH Barker, AC Dudley	British Journal of Cancer	2018
Targeting FBPase is an emerging novel approach for cancer therapy GM Liu, YM Zhang	Cancer Cell International	2018
Emerging cellular functions of the lipid metabolizing enzyme 15-Lipoxygenase-1 M Çolakoğlu, S Tunçer, S Banerjee	Cell Proliferation	2018
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease M Cosenza, S Pozzi	International journal of molecular sciences	2018
Class II histone deacetylases require P/Q-type Ca2+ channels and CaMKII to maintain gamma oscillations in the pedunculopontine nucleus FJ Urbano, V Bisagno, S Mahaffey, S Lee, E Garcia-Rill	Scientific Reports	2018
Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer D Brasacchio, RA Busuttil, T Noori, RW Johnstone, A Boussioutas, JA Trapani	Cell Death and Disease	2018
A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade CS Yen, CS Choy, WJ Huang, SW Huang, PY Lai, MC Yu, C Shiue, YF Hsu, MJ Hsu	Frontiers in pharmacology	2018
Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition K King, AT Hauser, J Melesina, W Sippl, M Jung	Molecules (Basel, Switzerland)	2018
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy A Singh, A Bishayee, A Pandey	Nutrients	2018
Rapid and transient oxygen consumption increase following acute HDAC/KDAC inhibition in Drosophila tissue L Becker, MS Nogueira, C Klima, MH de Angelis, S Peleg	Scientific Reports	2018
Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment CH White, N Beliakova-Bethell, SM Lada, MS Breen, TP Hurst, CA Spina, DD Richman, J Frater, G Magiorkinis, CH Woelk	Frontiers in immunology	2018
Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer X Kou, X Jiang, H Liu, X Wang, F Sun, J Han, J Fan, G Feng, Z Lin, L Jiang, Y Yang	Cancer Science	2018
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid S Yuille, N Reichardt, S Panda, H Dunbar, IE Mulder, D Nie	PloS one	2018
Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study SL Cramer, AL Miller, JG Pressey, TL Gamblin, EA Beierle, BD Kulbersh, PL Garcia, LN Council, R Radhakrishnan, SV Hendrix, DR Kelly, RG Watts, KJ Yoon	Frontiers in Oncology	2018
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status X Li, YK Peterson, ES Inks, RA Himes, J Li, Y Zhang, X Kong, CJ Chou	Journal of Medicinal Chemistry	2018
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells B Wang, H Lyu, S Pei, D Song, J Ni, B Liu	Cell cycle (Georgetown, Tex.)	2018
The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation B Paul, Y Li, T Tollefsbol	International journal of molecular sciences	2018
ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid J Wu, H Jiang, X Yang, H Zheng	Cancer Medicine	2018
Triple action Pt( iv ) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance E Petruzzella, R Sirota, I Solazzo, V Gandin, D Gibson	Chemical Science	2018
CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy RL Mintz, MA Gao, K Lo, YH Lao, M Li, KW Leong	Advanced Biosystems	2018
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI CH Weng, LY Chen, YC Lin, JY Shih, YC Lin, RY Tseng, AC Chiu, YH Yeh, C Liu, YT Lin, JM Fang, CC Chen	Oncogene	2018
The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay J Xia, H Hu, W Xue, XS Wang, S Wu	Journal of Enzyme Inhibition and Medicinal Chemistry	2018
Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism MY Jeong, YH Lin, SA Wennersten, KM Demos-Davies, MA Cavasin, JH Mahaffey, V Monzani, C Saripalli, P Mascagni, TB Reece, AV Ambardekar, HL Granzier, CA Dinarello, TA McKinsey	Science Translational Medicine	2018
Epigenetic regulation of neuroblastoma development K Durinck, F Speleman	Cell and Tissue Research	2018
Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations NR Valle, T Cheng, ME Irwin, H Donnella, MM Singh, J Chandra	Cancer Chemotherapy and Pharmacology	2018
Gene Therapy for Chronic HBV—Can We Eliminate cccDNA? K Bloom, M Maepa, A Ely, P Arbuthnot	Genes & development	2018
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses CR Brinkmann, JF Højen, TA Rasmussen, AS Kjær, R Olesen, PW Denton, L Østergaard, Z Ouyang, M Lichterfeld, X Yu, OS Søgaard, C Dinarello, M Tolstrup, A Fernandez-Sesma	mSphere	2018
Combination Therapies Targeting HDAC and IKK in Solid Tumors I Vancurova, MM Uddin, Y Zou, A Vancura	Trends in Pharmacological Sciences	2018
Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females Y huang, W Jian, J Zhao, G Wang	OncoTargets and therapy	2018
Cancer metabolism: New insights into classic characteristics Y Kato, T Maeda, A Suzuki, Y Baba	The Japanese dental science review	2018
Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins H Horita, A Law, K Middleton	Journal of visualized experiments : JoVE	2018
Targeting HDAC3 Activity with RGFP966 Protects Against Retinal Ganglion Cell Nuclear Atrophy and Apoptosis After Optic Nerve Injury HM Schmitt, CL Schlamp, RW Nickells	Journal of Ocular Pharmacology and Therapeutics	2018
The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity AT Negmeldin, JR Knoff, MK Pflum	European Journal of Medicinal Chemistry	2018
The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer J Zhang, W Zhou, X Wang, L Wang	RSC Advances	2018
Epigenetics in Amyotrophic Lateral Sclerosis: A Role for Histone Post Translational Modifications in Neurodegenerative Disease SA Bennett, R Tanaz, SN Cobos, MP Torrente	Translational research : the journal of laboratory and clinical medicine	2018
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors J Ungerstedt	International journal of molecular sciences	2018
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells J Wanek, M Gaisberger, M Beyreis, C Mayr, K Helm, F Primavesi, T Jäger, PD Fazio, M Jakab, A Wagner, D Neureiter, T Kiesslich	International journal of molecular sciences	2018
Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma KM Giles, BE Rosenbaum, M Berger, A Izsak, Y Li, II Bochaca, EV de Miera, J Wang, F Darvishian, H Zhong, I Osman	Journal of Investigative Dermatology	2018
Sodium butyrate induces autophagy in colorectal cancer cells through LKB1/AMPK signaling S Luo, Z Li, L Mao, S Chen, S Sun	Journal of Physiology and Biochemistry	2018
Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach SD Ros, L Aresu, S Ferraresso, E Zorzan, E Gaudio, F Bertoni, M Dacasto, M Giantin, A Ahmad	PloS one	2018
Biosynthesis of histone messenger RNA employs a specific 3' end endonuclease I Pettinati, P Grzechnik, CR de Almeida, J Brem, MA McDonough, S Dhir, NJ Proudfoot, CJ Schofield	eLife	2018
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma TN Teknos, J Grecula, A Agrawal, MO Old, E Ozer, R Carrau, S Kang, J Rocco, D Blakaj, V Diavolitsis, B Kumar, P Kumar, Q Pan, M Palettas, L Wei, R Baiocchi, P Savvides	Investigational New Drugs	2018
Co-repressor, co-activator and general transcription factor: the many faces of the Sin3 histone deacetylase (HDAC) complex GE Adams, A Chandru, SM Cowley	Biochemical Journal	2018
The antitumor effects of entinostat in ovarian cancer require adaptive immunity HJ Smith, TR McCaw, AI Londono, AA Katre, S MezaPerez, ES Yang, A Forero, DJ Buchsbaum, TD Randall, JM Straughn, LA Norian, RC Arend	Cancer	2018
Systematic review and meta-analysis of experimental studies evaluating the organ protective effects of histone deacetylase inhibitors SI Yusoff, M Roman, FY Lai, B Eagle-Hemming, GJ Murphy, T Kumar, M Wozniak	Translational research : the journal of laboratory and clinical medicine	2018
Induction of Krüppel-like factor 2 reduces K/BxN serum-induced arthritis M Das, D Laha, S Kanji, M Joseph, R Aggarwal, OH Iwenofu, VJ Pompili, MK Jain, H Das	Journal of Cellular and Molecular Medicine	2018
Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells Laurence Booth, Jane L Roberts, John Kirkwood, Andrew Poklepovic, Paul Dent	Advances in cancer research	2018
Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins J Tong, X Zheng, X Tan, R Fletcher, Z Nikolovska-Coleska, J Yu, L Zhang	Cancer research	2018
Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma CJ Yelton, SK Ray	Neuroimmunology and Neuroinflammation	2018
Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress Sato A, Asano T, Okubo K, Isono M, Asano T	Oncology research	2018
Histone Deacetylase Inhibitors: A Prospect in Drug Discovery YADAV R, MISHRA P, YADAV D		2018
Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma. Lin WC, Hsu FS, Kuo KL, Liu SH, Shun CT, Shi CS, Chang HC, Tsai YC, Lin MC, Wu JT, Kuo Y, Chow PM, Liao SM, Yang SP, Hong JY, Huang KH	Journal of Molecular Medicine	2018
Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic X. laevis Models of Retinitis Pigmentosa RY Vent-Schmidt, RH Wen, Z Zong, CN Chiu, BM Tam, CG May, OL Moritz	The Journal of neuroscience : the official journal of the Society for Neuroscience	2017
A G1‐like state allows HIV‐1 to bypass SAMHD1 restriction in macrophages P Mlcochova, KA Sutherland, SA Watters, C Bertoli, RA de Bruin, J Rehwinkel, SJ Neil, GM Lenzi, B Kim, A Khwaja, MC Gage, C Georgiou, A Chittka, S Yona, M Noursadeghi, GJ Towers, RK Gupta	The EMBO Journal	2017
Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial PE Georgoff, VC Nikolian, T Bonham, MP Pai, C Tafatia, I Halaweish, K To, K Watcharotone, A Parameswaran, R Luo, D Sun, HB Alam	Clinical Pharmacokinetics	2017
HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells KH Song, CH Choi, HJ Lee, SJ Oh, SR Woo, SO Hong, KH Noh, H Cho, EJ Chung, JH Kim, JY Chung, SM Hewitt, S Baek, KM Lee, C Yee, M Son, CP Mao, TC Wu, TW Kim	Cancer research	2017
Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs Y Wang, J Wallach, S Duane, Y Wang, J Wu, J Wang, A Adejare, H Ma	Drug design, development and therapy	2017
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3 SR Pasricha, PJ Lim, TL Duarte, C Casu, D Oosterhuis, K Mleczko-Sanecka, M Suciu, AR da Silva, K Al-Hourani, J Arezes, K McHugh, S Gooding, JN Frost, K Wray, A Santos, G Porto, E Repapi, N Gray, SJ Draper, N Ashley, E Soilleux, P Olinga, MU Muckenthaler, JR Hughes, S Rivella, TA Milne, AE Armitage, H Drakesmith	Nature Communications	2017
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC L Samaraweera, A Adomako, A Rodriguez-Gabin, HM McDaid	Scientific Reports	2017
Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties J Cai, B Li, Y Zhu, X Fang, M Zhu, M Wang, S Liu, X Jiang, J Zheng, XX Zhang, P Chen	EBioMedicine	2017
Dietary phytochemical PEITC restricts tumor development via modulation of epigenetic writers and erasers JE Park, Y Sun, SK Lim, JP Tam, M Dekker, H Chen, SK Sze	Scientific Reports	2017
Modulation of antitumor immunity with histone deacetylase inhibitors TR McCaw, TD Randall, A Forero, DJ Buchsbaum	Immunotherapy	2017
Chemical and structural biology of protein lysine deacetylases M YOSHIDA, N KUDO, S KOSONO, A ITO	Proceedings of the Japan Academy, Series B	2017
Histone Deacetylase Inhibitors as Anticancer Drugs T Eckschlager, J Plch, M Stiborova, J Hrabeta	International journal of molecular sciences	2017
Effect of entinostat on NK cell–mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis S Kiany, G Huang, ES Kleinerman	OncoImmunology	2017
Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors S LópezCobo, N Pieper, C Campos-Silva, EM GarcíaCuesta, HT Reyburn, A Paschen, M ValésGómez	OncoImmunology	2017
Epigenetics in cancer stem cells TB Toh, JJ Lim, EK Chow	Molecular Cancer	2017
Unlocking the chromatin of adenoid cystic carcinomas using HDAC inhibitors sensitize cancer stem cells to cisplatin and induces tumor senescence LO Almeida, DM Guimarães, MD Martins, MA Martins, KA Warner, JE Nör, RM Castilho, CH Squarize	Stem Cell Research	2017
Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma S Coni, AB Mancuso, LD Magno, G Sdruscia, S Manni, SM Serrao, D Rotili, E Spiombi, F Bufalieri, M Petroni, M Kusio-Kobialka, ED Smaele, E Ferretti, C Capalbo, A Mai, P Niewiadomski, I Screpanti, LD Marcotullio, G Canettieri	Scientific Reports	2017
Glycolytic reprogramming through PCK2 regulates tumor initiation of prostate cancer cells J Zhao, J Li, TW Fan, SX Hou	Oncotarget	2017
Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes E Dirice, RW Ng, R Martinez, J Hu, FF Wagner, EB Holson, BK Wagner, RN Kulkarni	The Journal of biological chemistry	2017
Targeting histone methylation for colorectal cancer T Huang, C Lin, LL Zhong, L Zhao, G Zhang, A Lu, J Wu, Z Bian	Therapeutic advances in gastroenterology	2017
Press-pulse: a novel therapeutic strategy for the metabolic management of cancer TN Seyfried, G Yu, JC Maroon, DP DAgostino	Nutrition & Metabolism	2017
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats D Brocks, CR Schmidt, M Daskalakis, HS Jang, NM Shah, D Li, J Li, B Zhang, Y Hou, S Laudato, DB Lipka, J Schott, H Bierhoff, Y Assenov, M Helf, A Ressnerova, S Islam, AM Lindroth, S Haas, M Essers, CD Imbusch, B Brors, I Oehme, O Witt, M Lübbert, JP Mallm, K Rippe, R Will, D Weichenhan, G Stoecklin, C Gerhäuser, CC Oakes, T Wang, C Plass	Nature Genetics	2017
Chemical optogenetic modulation of inflammation and immunity B Parasar, PV Chang	Chemical Science	2017
Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer KC Park, SM Kim, JY Jeon, BW Kim, HK Kim, HJ Chang, YS Lee, SY Kim, SH Choi, CS Park, HS Chang	Neoplasia (New York, N.Y.)	2017
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 SJ Hogg, SJ Vervoort, S Deswal, CJ Ott, J Li, LA Cluse, PA Beavis, PK Darcy, BP Martin, A Spencer, AK Traunbauer, I Sadovnik, K Bauer, P Valent, JE Bradner, J Zuber, J Shortt, RW Johnstone	Cell Reports	2017
Development of a Reference Image Collection Library for Histopathology Image Processing, Analysis and Decision Support Systems Research S Kostopoulos, P Ravazoula, P Asvestas, I Kalatzis, G Xenogiannopoulos, D Cavouras, D Glotsos	Journal of Digital Imaging	2017
Polycistronic tRNA and CRISPR guide-RNA enables highly efficient multiplexed genome engineering in human cells F Dong, K Xie, Y Chen, Y Yang, Y Mao	Biochemical and Biophysical Research Communications	2017
HDAC10 as a potential therapeutic target in ovarian cancer MM Islam, T Banerjee, CZ Packard, S Kotian, K Selvendiran, DE Cohn, JD Parvin	Gynecologic Oncology	2017
Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase I Raji, F Yadudu, E Janeira, S Fathi, L Szymczak, JR Kornacki, K Komatsu, JD Li, M Mrksich, AK Oyelere	Bioorganic & Medicinal Chemistry	2017
Quantitative measurement of intracellular HDAC1/2 drug occupancy using a trans-cyclooctene largazole thiol probe H Xu, LR Roberts, S Chou, B Pierce, A Narayanan, LH Jones	MedChemComm	2017
Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors I Raji, K Ahluwalia, AK Oyelere	Bioorganic & Medicinal Chemistry Letters	2017
Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity AT Negmeldin, G Padige, AV Bieliauskas, MK Pflum	ACS Medicinal Chemistry Letters	2017
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor BJ North, I Almeciga-Pinto, D Tamang, M Yang, SS Jones, SN Quayle, JS Castresana	PloS one	2017
Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression J Yang, X Jin, Y Yan, Y Shao, Y Pan, LR Roberts, J Zhang, H Huang, J Jiang	Scientific Reports	2017
Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array M Partolina, HC Thoms, KG MacLeod, G Rodriguez-Blanco, MN Clarke, AV Venkatasubramani, R Beesoo, V Larionov, VS Neergheen-Bhujun, B Serrels, H Kimura, NO Carragher, A Kagansky	Cell Death Discovery	2017
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine M Cosenza, M Civallero, L Marcheselli, S Sacchi, S Pozzi	Apoptosis	2017
The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer JM Spangle, TM Roberts, JJ Zhao	Biochimica et Biophysica Acta (BBA) - Reviews on Cancer	2017
Epigenome mapping highlights chromatin-mediated gene regulation in the protozoan parasite Trichomonas vaginalis MJ Song, M Kim, Y Choi, M Yi, J Kim, SJ Park, TS Yong, HP Kim	Scientific Reports	2017
Epigenetics in Stroke Recovery H Kassis, A Shehadah, M Chopp, Z Zhang	Genes & development	2017
The transformation of the nuclear nanoarchitecture in human field carcinogenesis GM Bauer, Y Stypula-Cyrus, H Subramanian, L Cherkezyan, P Viswanathan, D Zhang, R Iyengar, S Bagalkar, J Derbas, T Graff, S Gladstein, LM Almassalha, JE Chandler, HK Roy, V Backman	Future Science OA	2017
Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK L Hegedüs, R Padányi, J Molnár, K Pászty, K Varga, I Kenessey, E Sárközy, M Wolf, M Grusch, Z Hegyi, L Homolya, C Aigner, T Garay, B Hegedüs, J Tímár, E Kállay, Á Enyedi	Frontiers in Oncology	2017
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics S Chhabra	Pharmaceuticals (Basel, Switzerland)	2017
Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach KC Hsu, CY Liu, TE Lin, JH Hsieh, TY Sung, HJ Tseng, JM Yang, WJ Huang	Scientific Reports	2017
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma AC Jaime-Ramirez, JG Yu, E Caserta, JY Yoo, J Zhang, TJ Lee, C Hofmeister, JH Lee, B Kumar, Q Pan, P Kumar, R Baiocchi, T Teknos, F Pichiorri, B Kaur, M Old	Molecular Therapy - Oncolytics	2017
Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine KM Coyle, JE Boudreau, P Marcato	BioMed Research International	2017
Epigenetic regulation of RTK signaling JM Spangle, TM Roberts	Journal of Molecular Medicine	2017
Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition Y Yin, M Zhang, RG Dorfman, Y Li, Z Zhao, Y Pan, Q Zhou, S Huang, S Zhao, Y Yao, X Zou	Cell Death and Disease	2017
Molecular structures guide the engineering of chromatin SJ Tekel, KA Haynes	Nucleic Acids Research	2017
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications T Harada, H Ohguchi, Y Grondin, S Kikuchi, M Sagawa, YT Tai, R Mazitschek, T Hideshima, KC Anderson	Leukemia	2017
The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity AT Negmeldin, MK Pflum	Bioorganic & Medicinal Chemistry Letters	2017
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives D Lu, J Yan, L Wang, H Liu, L Zeng, M Zhang, W Duan, Y Ji, J Cao, M Geng, A Shen, Y Hu	ACS Medicinal Chemistry Letters	2017
Role of HDAC9-FoxO1 Axis in the Transcriptional Program Associated with Hepatic Gluconeogenesis J Chen, Z Zhang, N Wang, M Guo, X Chi, Y Pan, J Jiang, J Niu, S Ksimu, JZ Li, X Chen, Q Wang	Scientific Reports	2017
Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications P Chaiyawat, D Pruksakorn, A Phanphaisarn, P Teeyakasem, J Klangjorhor, J Settakorn	Modern Pathology	2017
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) G Bug, A Burchert, EM Wagner, N Kröger, T Berg, S Güller, SK Metzelder, A Wolf, S Hünecke, P Bader, J Schetelig, H Serve, OG Ottmann	Leukemia	2017
Metabolic programming of the epigenome: host and gut microbial metabolite interactions with host chromatin KA Krautkramer, RS Dhillon, JM Denu, HV Carey	Translational Research	2017
B1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB MH Cheng, YH Wong, CM Chang, CC Yang, SH Chen, CL Yuan, HM Kuo, CY Yang, HF Chiu	International journal of molecular medicine	2017
Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells DH Raulet, A Marcus, L Coscoy	Immunological Reviews	2017
Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway S Saito, Y Zhuang, B Shan, S Danchuk, F Luo, M Korfei, A Guenther, JA Lasky, Q Ding	PloS one	2017
WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade: WMJ-8-B induced cancer cell death via SHP-1 YF Chuang, SW Huang, YF Hsu, MC Yu, G Ou, WJ Huang, MJ Hsu	British Journal of Pharmacology	2017
Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells HR Gatla, Y Zou, MM Uddin, I Vancurova	Oncotarget	2017
Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells XQ Wang, HM Bai, ST Li, H Sun, LZ Min, BB Tao, J Zhong, B Li	Oncotarget	2017
CRISPR-mediated HDAC2 disruption identifies two distinct classes of target genes in human cells P Somanath, RH Klein, PS Knoepfler, R Mantovani	PloS one	2017
Meta-analysis of SIRT1 expression as a prognostic marker for overall survival in gastrointestinal cancer S Wu, J Jiang, J Liu, X Wang, Y Gan, Y Tang	Oncotarget	2017
Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo L Lu, K Li, YH Mao, H Qu, B Yao, WW Zhong, B Ma, ZY Wang	International journal of oncology	2017
HDAC Inhibitors Disrupt Programmed Resistance to Apoptosis During Drosophila Development Y Kang, K Marischuk, GD Castelvecchi, A Bashirullah	G3: Genes\|Genomes\|Genetics	2017
Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells X Ma, J Wang, J Liu, Q Mo, X Yan, D Ma, H Duan	Oncology Letters	2017
Regulation, Function, and Detection of Protein Acetylation in Bacteria VJ Carabetta, IM Cristea, W Margolin	Journal of bacteriology	2017
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms T Nguyen, R Parker, E Hawkins, B Holkova, V Yazbeck, A Kolluri, M Kmieciak, M Rahmani, S Grant	Oncotarget	2017
Novel hydroxamates potentiated in vitro activity of fluconazole against Candida albicans M Paul-Satyaseela, P Hariharan, T Bharani, JS Franklyne, T Selvakumar, K Bharathimohan, CV Kumar, V Kachhadia, S Narayanan, S Rajagopal, G Balasubramanian	Journal of Natural Science, Biology, and Medicine	2017
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study V Ribrag, WS Kim, R Bouabdallah, ST Lim, B Coiffier, A Illes, B Lemieux, MJ Dyer, F Offner, Z Felloussi, I Kloos, Y Luan, R Vezan, T Graef, F Morschhauser	Haematologica	2017
Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells A Grabarska, JJ Łuszczki, E Nowosadzka, E Gumbarewicz, W Jeleniewicz, M Dmoszyńska-Graniczka, K Kowalczuk, K Kupisz, K Polberg, A Stepulak	Journal of Cancer	2017
Advances in epigenetic glioblastoma therapy DH Lee, HW Ryu, HR Won, SH Kwon	Oncotarget	2017
Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells BR You, BR Han, WH Park	Oncotarget	2017
Epigenetic reprogramming in liver fibrosis and cancer CL Wilson, DA Mann, LA Borthwick	Advanced Drug Delivery Reviews	2017
Novel histone deacetylase inhibitor N25 exerts anti-tumor effects and induces autophagy in human glioma cells by inhibiting HDAC3 X Sun, Y Qu, A Ni, G Wang, W Huang, Z Chen, Z Lv, S Zhang, H Lindsay, S Zhao, X Li, B Feng	Oncotarget	2017
Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines E Bernhart, N Stuendl, H Kaltenegger, C Windpassinger, N Donohue, A Leithner, B Lohberger	Oncotarget	2017
Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides J Liu, M Bhadra, JR Sinnakannu, WL Yue, CW Tan, F Rigo, ST Ong, X Roca	Oncotarget	2017
The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts X Shi, A Tasdogan, F Huang, Z Hu, SJ Morrison, RJ DeBerardinis	Science Advances	2017
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial Y Oki, KR Kelly, I Flinn, MR Patel, R Gharavi, A Ma, J Parker, A Hafeez, D Tuck, A Younes	Haematologica	2017
Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex classï¿½I-related chainï¿½Aï¿½andï¿½B in cancer cells N Nakajima, A Niimi, M Isono, T Oike, H Sato, T Nakano, A Shibata	Oncology reports	2017
Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation JI Yu, C Choi, SW Shin, A Son, GH Lee, SY Kim, HC Park	Scientific Reports	2017
Acetylation and deacetylation in cancer stem-like cells N Liu, S Li, N Wu, KS Cho	Oncotarget	2017
Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway XF Liu, Q Zhou, R Hassan, I Pastan	Oncotarget	2017
Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates G Lopez, D Braggio, A Zewdu, L Casadei, K Batte, HK Bid, D Koller, P Yu, OH Iwenofu, A Strohecker, E Choy, D Lev, R Pollock, IV Lebedeva	PloS one	2017
The Roles of Glycodelin in Cancer Development and Progression J Cui, Y Liu, X Wang	Frontiers in immunology	2017
Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors H Abdelkarim, R Neelarapu, A Madriaga, AS Vaidya, I Kastrati, B Karumudi, Y Wang, TY Taha, GR Thatcher, J Frasor, PA Petukhov	ChemMedChem	2017
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors NJ Porter, A Mahendran, R Breslow, DW Christianson	Proceedings of the National Academy of Sciences	2017
Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis M Zhang, Y Yin, RG Dorfman, T Zou, Y Pan, Y Li, Y Wang, Q Zhou, L Zhou, B Kong, H Friess, J Zhang, S Zhao, L Wang, X Zou	Oncotarget	2017
Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer ND Facompre, KM Harmeyer, V Sahu, PA Gimotty, AK Rustgi, H Nakagawa, D Basu	Oncotarget	2017
Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations T Yamada, JM Amann, A Tanimoto, H Taniguchi, T Shukuya, C Timmers, S Yano, K Shilo, DP Carbone	Molecular cancer therapeutics	2017
Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis H Zhang, D Wang, M Li, L Plecitá-Hlavatá, A DAlessandro, J Tauber, S Riddle, S Kumar, A Flockton, BA McKeon, MG Frid, JA Reisz, P Caruso, KC Kasmi, P Ježek, NW Morrell, CJ Hu, KR Stenmark	Circulation	2017
A simple toolset to identify endogenous post-translational modifications for a target protein: a snapshot of the EGFR signaling pathway H Horita, A Law, S Hong, K Middleton	Bioscience Reports	2017
Cell-Surface and Nuclear Receptors in the Colon as Targets for Bacterial Metabolites and Its Relevance to Colon Health Sivaprakasam S, Bhutia YD, Ramachandran S, Ganapathy V	Nutrients	2017
Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Gilardini Montani MS, Granato M, Santoni C, Del Porto P, Merendino N, D'Orazi G, Faggioni A, Cirone M	Cellular oncology (Dordrecht)	2017
The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis. Yu Y, Cao F, Yu X, Zhou P, Di Q, Lei J, Tai Y, Wu H, Li X, Wang X, Zhang W, Li P, Li Y	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2017
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma Yoichi Imai, Eri Ohta, Shu Takeda, M.D., Ph.D., Satoko Sunamura, Mariko Ishibashi, Hideto Tamura, Yan-hua Wang, Atsuko Deguchi, Junji Tanaka, Yoshiro Maru, Toshiko Motoji	JCI Insight	2016
Targeting BTK through microRNA in chronic lymphocytic leukemia A Bottoni, L Rizzotto, TH Lai, C Liu, LL Smith, R Mantel, S Reiff, D El-Gamal, K Larkin, AJ Johnson, R Lapalombella, A Lehman, W Plunkett, JC Byrd, JS Blachly, JA Woyach, D Sampath	Blood	2016
G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis L Nogués, C Reglero, V Rivas, A Salcedo, V Lafarga, M Neves, P Ramos, M Mendiola, A Berjón, K Stamatakis, XZ Zhou, KP Lu, D Hardisson, F Mayor, P Penela	EBioMedicine	2016
Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma Y Furukawa, J Kikuchi	International Journal of Hematology	2016
Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model P Zhu, CJ Sieben, X Xu, PC Harris, X Lin	Human Molecular Genetics	2016
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases EE Hull, MK Montgomery, KJ Leyva	BioMed Research International	2016
Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration A Kimura, K Namekata, X Guo, C Harada, T Harada	International journal of molecular sciences	2016
Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib Y Jin, Y Yao, L Chen, X Zhu, B Jin, Y Shen, J Li, X Du, Y Lu, S Jiang, J Pan	Theranostics	2016
Epigenetic regulation of epithelial–mesenchymal transition L Sun, J Fang	Cellular and Molecular Life Sciences	2016
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma H Zheng, W Zhao, C Yan, CC Watson, M Massengill, M Xie, C Massengill, DR Noyes, GV Martinez, R Afzal, Z Chen, X Ren, SJ Antonia, EB Haura, B Ruffell, AA Beg	Clinical cancer research	2016
Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma A Mishra, KL Perle, S Kwiatkowski, LA Sullivan, GH Sams, J Johns, DP Curphey, J Wen, K McConnell, J Qi, H Wong, G Russo, J Zhang, G Marcucci, JE Bradner, P Porcu, MA Caligiuri	Cancer Discovery	2016
The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways I Hrgovic, M Doll, J Kleemann, XF Wang, N Zoeller, A Pinter, S Kippenberger, R Kaufmann, M Meissner	BMC Cancer	2016
Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer VF Merino, N Nguyen, K Jin, H Sadik, S Cho, P Korangath, L Han, YM Foster, XC Zhou, Z Zhang, RM Connolly, V Stearns, SZ Ali, C Adams, Q Chen, D Pan, DL Huso, P Ordentlich, A Brodie, S Sukumar	Cancer research	2016
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR L Zhou, S Chen, Y Zhang, M Kmieciak, Y Leng, L Li, H Lin, KA Rizzo, CI Dumur, A Ferreira-Gonzalez, M Rahmani, L Povirk, S Chalasani, AJ Berger, Y Dai, S Grant	Blood	2016
Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure C Tokheim, R Bhattacharya, N Niknafs, DM Gygax, R Kim, M Ryan, DL Masica, R Karchin	Cancer research	2016
Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer S Duffy, HK Fam, YK Wang, EB Styles, JH Kim, JS Ang, T Singh, V Larionov, SP Shah, B Andrews, CF Boerkoel, P Hieter	Proceedings of the National Academy of Sciences	2016
Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1 M Hulsurkar, Z Li, Y Zhang, X Li, D Zheng, W Li	Oncogene	2016
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings B Ball, A Zeidan, SD Gore, T Prebet	Leukemia & Lymphoma	2016
Epigenetic Determinants of Cancer SB Baylin, PA Jones	Cold Spring Harbor perspectives in biology	2016
Transcriptional Selectivity of Epigenetic Therapy in Cancer T Sato, M Cesaroni, W Chung, S Panjarian, A Tran, J Madzo, Y Okamoto, H Zhang, X Chen, J Jelinek, JP Issa	Cancer research	2016
HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies P Peixoto, A Blomme, B Costanza, R Ronca, S Rezzola, AP Palacios, L Schoysman, S Boutry, N Goffart, O Peulen, P Maris, ED Valentin, V Hennequière, E Bianchi, A Henry, P Meunier, B Rogister, RN Muller, P Delvenne, A Bellahcène, V Castronovo, A Turtoi	Oncogene	2016
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs P Papanagnou, T Stivarou, M Tsironi	Pharmaceuticals (Basel, Switzerland)	2016
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? S Baig, I Seevasant, J Mohamad, A Mukheem, HZ Huri, T Kamarul	Cell Death and Disease	2016
Epigenetic Therapeutics: A New Weapon in the War Against Cancer N Ahuja, AR Sharma, SB Baylin	Annual Review of Medicine	2016
Downregulation of the Ca 2+ -activated K + channel K C a 3.1 by histone deacetylase inhibition in human breast cancer cells S Ohya, S Kanatsuka, N Hatano, H Kito, A Matsui, M Fujimoto, S Matsuba, S Niwa, P Zhan, T Suzuki, K Muraki	Pharmacology Research & Perspectives	2016
Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma IV Tiper, TJ Webb	Cancer Immunology, Immunotherapy	2016
HDAC5 controls the functions of Foxp3 + T-regulatory and CD8 + T cells: HDAC5 controls TREG and CD8 T cell function H Xiao, J Jiao, L Wang, S O'Brien, K Newick, LC Wang, E Falkensammer, Y Liu, R Han, V Kapoor, FK Hansen, T Kurz, WW Hancock, UH Beier	International Journal of Cancer	2016
Epigenetic modulators as therapeutic targets in prostate cancer I Graça, E Pereira-Silva, R Henrique, G Packham, SJ Crabb, C Jerónimo	Clinical Epigenetics	2016
Development of a Fluorinated Class-I HDAC Radiotracer Reveals Key Chemical Determinants of Brain Penetrance MG Strebl, C Wang, FA Schroeder, MS Placzek, HY Wey, GC van de Bittner, R Neelamegam, JM Hooker	ACS Chemical Neuroscience	2016
ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer M Napoli, A Venkatanarayan, P Raulji, BA Meyers, W Norton, LS Mangala, AK Sood, C Rodriguez-Aguayo, G Lopez-Berestein, H Vin, M Duvic, MB Tetzlaff, JL Curry, AH Rook, HA Abbas, C Coarfa, PH Gunaratne, KY Tsai, ER Flores	Cancer Cell	2016
Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines RJ Fecek, WJ Storkus	Immunotherapy	2016
Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth MS Nakazawa, TS Eisinger-Mathason, N Sadri, JD Ochocki, TP Gade, RK Amin, MC Simon	Nature Communications	2016
Histone Deacetylase Inhibitors Increase p27 Kip1 by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation A Borriello, S Naviglio, D Bencivenga, I Caldarelli, A Tramontano, MC Speranza, E Stampone, L Sapio, A Negri, A Oliva, AA Sinisi, A Spina, FD Ragione	Oxidative medicine and cellular longevity	2016
Molecular underpinnings of HDAC inhibition revealed CM Adams, CM Eischen	Cell cycle (Georgetown, Tex.)	2016
Rapid Identification of Potential Drugs for Diabetic Nephropathy Using Whole-Genome Expression Profiles of Glomeruli J Shi, S Jiang, D Qiu, W Le, X Wang, Y Lu, Z Liu	BioMed Research International	2016
Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma CM Adams, CM Eischen	Cell Death and Differentiation	2016
Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and Epac pathways in human lung cancer cells JA Lim, YS Juhnn	Experimental & molecular medicine	2016
Loss of histone deacetylase HDAC1 induces cell death in Drosophila epithelial cells through JNK and Hippo signaling T Zhang, Z Sheng, W Du	Mechanisms of Development	2016
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside T Harada, T Hideshima, KC Anderson	International Journal of Hematology	2016
Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms L Wang, H Li, Y Ren, S Zou, W Fang, X Jiang, L Jia, M Li, X Liu, X Yuan, G Chen, J Yang, C Wu	Cell Death and Disease	2016
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition M Jonsson, HB Ragnum, CH Julin, A Yeramian, T Clancy, KA Frikstad, T Seierstad, T Stokke, X Matias-Guiu, AH Ree, K Flatmark, H Lyng	British Journal of Cancer	2016
HDAC inhibitors cause site-specific chromatin remodeling at PU.1-bound enhancers in K562 cells CL Frank, D Manandhar, R Gordân, GE Crawford	Epigenetics & chromatin	2016
Disubstituted naphthyl β-D-xylopyranosides: Synthesis, GAG priming, and histone acetyltransferase (HAT) inhibition K Thorsheim, A Persson, A Siegbahn, E Tykesson, G Westergren-Thorsson, K Mani, U Ellervik	Glycoconjugate Journal	2016
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia E Ceccacci, S Minucci	British Journal of Cancer	2016
HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine P Aramsangtienchai, NA Spiegelman, B He, SP Miller, L Dai, Y Zhao, H Lin	ACS chemical biology	2016
Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition MK Davis, JJ Daggett, AS Pascual, JM Lam, KJ Leyva, KE Cooper, EE Hull	BMC Cancer	2016
The role of enhancers in cancer I Sur, J Taipale	Nature Reviews Cancer	2016
Epigenetic Regulation of Bone Remodeling and Its Impacts in Osteoporosis C Ghayor, F Weber	International journal of molecular sciences	2016
Insights into the activation mechanism of class I HDAC complexes by inositol phosphates PJ Watson, CJ Millard, AM Riley, NS Robertson, LC Wright, HY Godage, SM Cowley, AG Jamieson, BV Potter, JW Schwabe	Nature Communications	2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial A Younes, JG Berdeja, MR Patel, I Flinn, JF Gerecitano, SS Neelapu, KR Kelly, AR Copeland, A Akins, MS Clancy, L Gong, J Wang, A Ma, JL Viner, Y Oki	The Lancet Oncology	2016
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition Y Hai, DW Christianson	Nature Chemical Biology	2016
Metabolic control of epigenetics in cancer A Kinnaird, S Zhao, KE Wellen, ED Michelakis	Nature Reviews Cancer	2016
Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer F Gong, LY Chiu, KM Miller, DA Gordenin	PLoS genetics	2016
EXPRESS: Histone hyperacetylation modulates spinal type II metabotropic glutamate receptor alleviating stress-induced visceral hypersensitivity in female rats DY Cao, G Bai, Y Ji, JM Karpowicz, RJ Traub	Molecular Pain	2016
Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer T Kavlashvili, Y Jia, D Dai, X Meng, KW Thiel, KK Leslie, S Yang, W Xu	PloS one	2016
Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay CW Hsu, D Shou, R Huang, T Khuc, S Dai, W Zheng, C Klumpp-Thomas, M Xia	Journal of biomolecular screening	2016
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors JS Brown, B O'Carrigan, SP Jackson, TA Yap	Cancer Discovery	2016
The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat NC Hoffend, WJ Magner, TB Tomasi	Epigenetics : official journal of the DNA Methylation Society	2016
Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer SJ Bultman	Molecular Nutrition & Food Research	2016
Epigenetics in Cancer: A Hematological Perspective M Stahl, N Kohrman, SD Gore, TK Kim, AM Zeidan, T Prebet, DJ Kwiatkowski	PLoS genetics	2016
Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy E Kalanxhi, K Risberg, IS Barua, S Dueland, S Waagene, SN Andersen, SJ Pettersen, JM Lindvall, KR Redalen, K Flatmark, AH Ree	Cancer Research and Treatment	2016
A Herpesviral induction of RAE-1 NKG2D ligand expression occurs through release of HDAC mediated repression TT Greene, M Tokuyama, GM Knudsen, M Kunz, J Lin, AL Greninger, VR DeFilippis, JL DeRisi, DH Raulet, L Coscoy	eLife	2016
Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma V Pillonel, N Reichert, C Cao, MR Heideman, T Yamaguchi, G Matthias, A Tzankov, P Matthias	Scientific Reports	2016
CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma MP Phelps, JN Bailey, T Vleeshouwer-Neumann, EY Chen	Proceedings of the National Academy of Sciences	2016
Sézary Syndrome: Clinical and Biological Aspects R Kohnken, S Fabbro, J Hastings, P Porcu, A Mishra	Current Hematologic Malignancy Reports	2016
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies Y Imai, Y Maru, J Tanaka	Cancer Science	2016
Impaired histone deacetylases 5 and 6 expression mimics the effects of obesity and hypoxia on adipocyte function J Bricambert, D Favre, S Brajkovic, A Bonnefond, R Boutry, R Salvi, V Plaisance, M Chikri, G Chinetti-Gbaguidi, B Staels, V Giusti, R Caiazzo, F Pattou, G Waeber, P Froguel, A Abderrahmani	Molecular Metabolism	2016
Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study K Goto, DA Annan, T Morita, W Li, R Muroyama, Y Matsubara, S Ito, R Nakagawa, Y Tanoue, M Jinushi, N Kato	Scientific Reports	2016
HDACs and HDAC Inhibitors in Cancer Development and Therapy Y Li, E Seto	Cold Spring Harbor Perspectives in Medicine	2016
The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target MD Martile, DD Bufalo, D Trisciuoglio	Oncotarget	2016
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice VS Gil, G Bhagat, L Howell, J Zhang, CH Kim, S Stengel, F Vega, A Zelent, K Petrie	Disease models & mechanisms	2016
Activated Transcription Factor 3 in Association with Histone Deacetylase 6 Negatively Regulates MicroRNA 199a2 Transcription by Chromatin Remodeling and Reduces Endothelin-1 Expression C Li, Y Zhou, A Loberg, SM Tahara, P Malik, VK Kalra	Molecular and cellular biology	2016
LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition SK Krönung, U Beyer, ML Chiaramonte, D Dolfini, R Mantovani, M Dobbelstein	Oncotarget	2016
Inhibition of store‑operated Ca2+ entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate W Huang, C Ren, G Huang, J Liu, W Liu, L Wang, B Zhu, X Feng, J Shi, J Li, X Xia, W Jia, J Chen, Y Chen, X Jiang	Oncology Letters	2016
Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis K Lyberg, HA Ali, J Grootens, M Kjellander, M Tirfing, M Arock, H Hägglund, G Nilsson, J Ungerstedt	Oncotarget	2016
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models P Huang, I Almeciga-Pinto, M Jarpe, JH van Duzer, R Mazitschek, M Yang, SS Jones, SN Quayle	Oncotarget	2016
Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma V Jeannot, B Busser, L Vanwonterghem, S Michallet, S Ferroudj, M Cokol, JL Coll, M Ozturk, A Hurbin	OncoTargets and therapy	2016
Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells J Bhat, J Sosna, J Fritsch, ES Quabius, S Schütze, S Zeissig, O Ammerpohl, D Adam, D Kabelitz	Oncotarget	2016
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW	Oncotarget	2016
Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers Yang AY, Kim H, Li W, Kong AN	Current topics in medicinal chemistry	2016
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability. Chao MW, Chu PC, Chuang HC, Shen FH, Chou CC, Hsu EC, Himmel LE, Huang HL, Tu HJ, Kulp SK, Teng CM, Chen CS	Oncotarget	2016
Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. Staberg M, Michaelsen SR, Rasmussen RD, Villingshøj M, Poulsen HS, Hamerlik P	Cellular oncology (Dordrecht)	2016
Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis YN Tang, WQ Ding, XJ Guo, XW Yuan, DM Wang, JG Song	Nature Communications	2015
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction CJ Whatcott, H Han, DD von Hoff	The Cancer Journal	2015
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine TD Ahrens, S Timme, J Hoeppner, J Ostendorp, S Hembach, M Follo, UT Hopt, M Werner, H Busch, M Boerries, S Lassmann	Epigenetics : official journal of the DNA Methylation Society	2015
Treatment of chronic kidney diseases with histone deacetylase inhibitors N Liu, S Zhuang	Frontiers in physiology	2015
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity K Cao, G Wang, W Li, L Zhang, R Wang, Y Huang, L Du, J Jiang, C Wu, X He, AI Roberts, F Li, AB Rabson, Y Wang, Y Shi	Oncogene	2015
Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies A Ediriwickrema, WM Saltzman	ACS Biomaterials Science & Engineering	2015
Epigenetics of the failing heart J Marín-García, AT Akhmedov	Heart Failure Reviews	2015
Histone Deacetylases in Bone Development and Skeletal Disorders EW Bradley, LR Carpio, AJ van Wijnen, ME McGee-Lawrence, JJ Westendorf	Physiological reviews	2015
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review R Camicia, HC Winkler, PO Hassa	Molecular Cancer	2015
An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer Z Yang, A Jones, M Widschwendter, AE Teschendorff	Genome biology	2015
Mutant p53: One, No One, and One Hundred Thousand D Walerych, K Lisek, GD Sal	Frontiers in Oncology	2015
Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma T Vleeshouwer-Neumann, M Phelps, TK Bammler, JW MacDonald, I Jenkins, EY Chen, JS Castresana	PloS one	2015
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies GM Matthews, P Mehdipour, LA Cluse, KJ Falkenberg, E Wang, M Roth, F Santoro, E Vidacs, K Stanley, CM House, JR Rusche, CR Vakoc, J Zuber, S Minucci, RW Johnstone	Blood	2015
Cardioprotection in ischaemia-reperfusion injury: novel mechanisms and clinical translation: Cardioprotection in ischaemia-reperfusion F Altamirano, ZV Wang, JA Hill	The Journal of Physiology	2015
Suberoylanilide hydroxamic acid suppresses hepatic stellate cells activation by HMGB1 dependent reduction of NF- κ B1 W Wang, M Yan, Q Ji, J Lu, Y Ji, J Ji	PeerJ	2015
Prospects for the development of epigenetic drugs for CNS conditions M Szyf	Nature Reviews Drug Discovery	2015
Potential of epigenetic therapies in the management of solid tumors VM Valdespino-Gomez, PM Valdespino	Cancer management and research	2015
Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis FÃ Lamoth, PR Juvvadi, WJ Steinbach	Frontiers in microbiology	2015
Changing the Selectivity of p300 by Acetyl-CoA Modulation of Histone Acetylation RA Henry, YM Kuo, V Bhattacharjee, TJ Yen, AJ Andrews	ACS chemical biology	2015
Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo JM Gajer, SD Furdas, A Gründer, M Gothwal, U Heinicke, K Keller, F Colland, S Fulda, HL Pahl, I Fichtner, W Sippl, M Jung	Oncogenesis	2015
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression P Raha, S Thomas, KT Thurn, J Park, PN Munster	Breast Cancer Research	2015
Novel and emerging targeted-based cancer therapy agents and methods M Hojjat-Farsangi	Tumor Biology	2015
HDAC4 Degradation Mediates HDAC Inhibition-Induced Protective Effects Against Hypoxia/Reoxygenation Injury: HDAC4 DEGRADATION MEDIATES HDAC INHIBITION-INDUCED J Du, L Zhang, S Zhuang, GJ Qin, T Zhao	Journal of Cellular Physiology	2015
Benchmarking methods and data sets for ligand enrichment assessment in virtual screening J Xia, EL Tilahun, TE Reid, L Zhang, XS Wang	Methods	2015
Panobinostat: First Global Approval KP Garnock-Jones	Drugs	2015
Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin M Kai, N Kanaya, SV Wu, C Mendez, D Nguyen, T Luu, S Chen	Breast Cancer Research and Treatment	2015
Strategies for Correcting Very Long Chain Acyl-CoA Dehydrogenase Deficiency M Tenopoulou, J Chen, J Bastin, MJ Bennett, H Ischiropoulos, PT Doulias	The Journal of biological chemistry	2015
Accessing DNA damage in chromatin: Preparing the chromatin landscape for base excision repair Y Rodriguez, JM Hinz, MJ Smerdon	DNA repair	2015
Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs) MT Mackmull, M Iskar, L Parca, S Singer, P Bork, A Ori, M Beck	Molecular & cellular proteomics : MCP	2015
Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties A Ali, TJ Burns, JD Lucrezi, SW May, GR Green, DF Matesic	Investigational New Drugs	2015
Chronic hepatitis B: A wave of new therapies on the horizon TM Block, S Rawat, CL Brosgart	Antiviral Research	2015
Epigenetic activities of flavonoids in the prevention and treatment of cancer C Busch, M Burkard, C Leischner, UM Lauer, J Frank, S Venturelli	Clinical Epigenetics	2015
Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells T Yan-Fang, L Zhi-Heng, X Li-Xiao, F Fang, L Jun, L Gang, C Lan, W Na-Na, D Xiao-Juan, S Li-Chao, Z Wen-Li, X Pei-Fang, Z He, S Guang-Hao, L Yan-Hong, L Yi-Ping, X Yun-Yun, Z Hui-Ting, W Yi, J Mei-Fang, L Lin, N Jian, H Shao-Yan, Z Xue-Ming, F Xing, W Jian, P Jian, YH Hsieh	PloS one	2015
Histone Deacetylases Exert Class-Specific Roles in Conditioning the Brain and Heart Against Acute Ischemic Injury SE Aune, DJ Herr, CJ Kutz, DR Menick	Frontiers in neurology	2015
Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation S Jang, XM Yu, S Odorico, M Clark, R Jaskula-Sztul, CM Schienebeck, KR Kupcho, AD Harrison, GN Winston-McPherson, W Tang, H Chen	Cancer Gene Therapy	2015
Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response JA Halsall, N Turan, M Wiersma, BM Turner	Epigenetics & chromatin	2015
Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review A Sawas, D Radeski, OA O'Connor	Therapeutic Advances in Hematology	2015
Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy W Szymanski, ME Ourailidou, WA Velema, FJ Dekker, BL Feringa	Chemistry - A European Journal	2015
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies D Markozashvili, V Ribrag, YS Vassetzky	Investigational New Drugs	2015
Modulators of alternative splicing as novel therapeutics in cancer S Oltean	World journal of clinical oncology	2015
Das Epigenom: Zielstruktur für innovative Therapiekonzepte beim Kopf- und Halskarzinom A Leipold, J Heß, K Zaoui	HNO	2015
Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors K Saijo, J Imamura, K Narita, A Oda, H Shimodaira, T Katoh, C Ishioka	Cancer Science	2015
“Fold Here”—Chemical Correctors in the Treatment of Epilepsy AL Hartman	Epilepsy Currents	2015
NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells JT Pai, CY Hsu, KT Hua, SY Yu, CY Huang, CN Chen, CH Liao, MS Weng	Molecules (Basel, Switzerland)	2015
Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo W Qi, W Zhang, H Edwards, R Chu, GJ Madlambayan, JW Taub, Z Wang, Y Wang, C Li, H Lin, Y Ge	Cancer biology & therapy	2015
Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer SM Kim, KC Park, JY Jeon, BW Kim, HK Kim, HJ Chang, SH Choi, CS Park, HS Chang	BMC Cancer	2015
Improving cancer immunotherapy with DNA methyltransferase inhibitors MH Saleh, L Wang, MS Goldberg	Cancer Immunology, Immunotherapy	2015
Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer A Brufsky	Clinical Medicine Insights. Oncology	2015
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies CM Adams, SW Hiebert, CM Eischen	Cancer research	2015
Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of Competitors S Venturelli, RG Belz, A Kämper, A Berger, K Horn, A Wegner, A Böcker, G Zabulon, T Langenecker, O Kohlbacher, F Barneche, D Weigel, UM Lauer, M Bitzer, C Becker	The Plant cell	2015
Combination therapy in combating cancer RB Mokhtari, TS Homayouni, N Baluch, E Morgatskaya, S Kumar, B Das, H Yeger	Oncotarget	2015
The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells C Campanella, A D'Anneo, AM Gammazza, CC Bavisotto, R Barone, S Emanuele, FL Cascio, E Mocciaro, S Fais, EC de Macario, AJ Macario, F Cappello, M Lauricella	Oncotarget	2015
The histone deacetylase inhibitor cambinol prevents acidic pHe-induced anterograde lysosome trafficking independently of sirtuin activity SS Dykes, E Friday, K Pruitt, JA Cardelli	Biochemistry and Biophysics Reports	2015
Pediatric Rhabdomyosarcoma. Shern JF, Yohe ME, Khan J	Critical Reviews in Oncogenesis	2015
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer Wei TT, Lin YC, Lin PH, Shih JY, Chou CW, Huang WJ, Yang YC, Hsiao PW, Chen CC	Oncotarget	2015
Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, Copland JA, Smallridge RC, Li Z, Shen M, Kebebew E	Oncotarget	2015
HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status Ou WB, Zhu J, Eilers G, Li X, Kuang Y, Liu L, Mariño-Enríquez A, Yan Z, Li H, Meng F, Zhou H, Sheng Q, Fletcher JA	Oncotarget	2015
Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib Hui KF, Yeung PL, Chiang AK	Oncotarget	2015
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. Ischenko I, Petrenko O, Hayman MJ	Oncotarget	2015
Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog Kumar B, Yadav A, Lang JC, Teknos TN, Kumar P	Genes & cancer	2015
Identification of small molecules that inhibit the histone chaperone Asf1 and its chromatin function. Seol JH, Song TY, Oh SE, Jo C, Choi A, Kim B, Park J, Hong S, Song I, Jung KY, Yang JH, Park H, Ahn JH, Han JW, Cho EJ	BMB Reports	2015
At the Tipping Point for Epigenetic Therapies in Cancer Peter A. Jones	Journal of Clinical Investigation	2014
Restoration of Impaired Endothelial MEF2 Function Rescues Pulmonary Arterial Hypertension J Kim, C Hwangbo, X Hu, Y Kang, I Papangeli, D Mehrotra, H Park, DL McLean, H Ju, SA Comhair, SC Erzurum, HJ Chun	Circulation	2014
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders KJ Falkenberg, RW Johnstone	Nature Reviews Drug Discovery	2014
Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer Z Li, Y Wang, C Yuan, Y Zhu, J Qiu, W Zhang, B Qi, H Wu, J Ye, H Jiang, J Yang, J Cheng	Laboratory Investigation	2014
Therapeutic targeting of tumor suppressor genes: Therapeutic Targeting of Tumors LG Morris, TA Chan	Cancer	2014
The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer D Khabele	Frontiers in Oncology	2014
Selective class IIa HDAC inhibitors: myth or reality ED Giorgio, E Gagliostro, C Brancolini	Cellular and Molecular Life Sciences	2014
A Potent HDAC Inhibitor, 1-Alaninechlamydocin, from a Tolypocladium sp. Induces G2/M Cell Cycle Arrest and Apoptosis in MIA PaCa-2 Cells L Du, AL Risinger, JB King, DR Powell, RH Cichewicz	Journal of Natural Products	2014
Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation MR Grimmer, S Stolzenburg, E Ford, R Lister, P Blancafort, PJ Farnham	Nucleic Acids Research	2014
Targeting the histone orthography of cancer: drugs for writers, erasers and readers: Histone orthography of cancer L Simó-Riudalbas, M Esteller	British Journal of Pharmacology	2014
The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies? MR Wills, E Poole, B Lau, B Krishna, JH Sinclair	Cellular and Molecular Immunology	2014
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma CV Andreu-Vieyra, JR Berenson	Therapeutic Advances in Hematology	2014
The effect of sulforaphane on histone deacetylase activity in keratinocytes: Differences between in vitro and in vivo analyses: HDAC INHIBITION IN KERATINOCYTES BY SF SE Dickinson, JJ Rusche, SL Bec, DJ Horn, J Janda, SH Rim, CL Smith, GT Bowden	Molecular Carcinogenesis	2014
Can genome engineering be used to target cancer-associated enhancers? MR Grimmer, PJ Farnham	Epigenomics	2014
Trial Watch: Proteasomal inhibitors for anticancer therapy F Obrist, G Manic, G Kroemer, I Vitale, L Galluzzi	Molecular & Cellular Oncology	2014
Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients MV Damme, E Crompot, N Meuleman, P Mineur, B Dessars, HE Housni, D Bron, L Lagneaux, B Stamatopoulos	Epigenetics : official journal of the DNA Methylation Society	2014
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001 V Ramakrishnan, T Kimlinger, M Timm, J Haug, SV Rajkumar, S Kumar	Leukemia Research	2014
Pan-Species Small Molecule Disruptors of Heterochromatin-Mediated Transcriptional Gene Silencing E Castonguay, SA White, A Kagansky, DJ St-Cyr, AG Castillo, C Brugger, R White, C Bonilla, M Spitzer, WC Earnshaw, T Schalch, K Ekwall, M Tyers, RC Allshire	Molecular and cellular biology	2014
Epigenetic control of gene function in schistosomes: a source of therapeutic targets? A Cabezas-Cruz	Frontiers in Genetics	2014
Epigenetic upregulation of metabotropic glutamate receptor 2 in the spinal cord attenuates oestrogen-induced visceral hypersensitivity DY Cao, G Bai, Y Ji, RJ Traub	Gut	2014
Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma LT Wang, SS Chiou, CY Chai, E Hsi, SN Wang, SK Huang, SH Hsu	Oncotarget	2014
Epigenetic advances in clinical neuroscience Abel T, Poplawski S	Dialogues in clinical neuroscience	2014
Pulmonary surfactant: an immunological perspective ZC Chroneos, Z Sever-Chroneos, VL Shepherd	Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology	2009

Advertisement